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Abstract 
Crosspresentation allows antigen presenting cells to present peptides 
from exogenously derived antigens onto MHC Class I for presentation to CD8+ T 
cells. Though this pathway shares key players with the Classical Class I and 
Class II pathways, several questions remain. A genomewide siRNA screen was 
performed to look for genes that selectively affected the crosspresentation or the 
Class II pathways. Among the genes identified in the screen was the Rab 
GTPase Rab39a. Rab39a was required for efficient crosspresentation but was 
dispensable for the presentation of endogenously expressed antigen. Both TAP-
dependent and independent antigen required Rab39a for efficient presentation. 
Rab39a localized to late endosomes and phagosomes, though interestingly it 
was not required for the Class II pathway. Analysis of phagosomes from Rab39a 
KO or rescued cells has shown that in the presence of Rab39a, phagosomes 
were enriched for the open form of MHC Class I as well as TAP1, a member of 
the peptide loading complex. The enriched open form of MHC-I was peptide 
receptive, suggesting that it could contribute to crosspresentation. Phagosomes 
from Rab39a positive cells had reduced degradative capability and had 
increased levels of Sec22b, a SNARE protein reported to deliver ER-golgi 
sourced cargo to phagosomes. Furthermore, inhibition of ER-golgi transport via 
brefeldin A abolished the phenotype conferred by Rab39a. Thus, we hypothesize 
that Rab39a mediates the delivery of ER-golgi derived cargo to the antigen 
containing phagosome. This delivery allows peptide receptive MHC-I, as well as 
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the peptide loading complex to reach the antigen, thereby facilitating 
crosspresentation. 
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CHAPTER I: A Genomewide SiRNA Screen Identifies Genes Important For 
The Crosspresentation And Class II Presentation Pathways 
 
I. Introduction 
A. Crosspresentation and its relevance 
The initiation of an effective T cell response begins with the stimulation of 
naïve T cells by antigen presenting cells (APCs). This stimulation is primarily 
mediated by the interaction between the T cell receptor and its cognate peptide-
MHC molecule presented on the APC surface. Peptide presented on MHC Class 
I stimulate CD8+ T cells to become cytolytic (CTL) and produce cytokines. 
Meanwhile, peptides presented on MHC Class II stimulate CD4+ T cells, which 
have a variety of functions including cytokine production and in some cases, 
cytolytic function as well.  
Traditionally, it was thought that the presentation of peptides on MHC 
Class I vs Class II molecules was based solely on the source of antigen. MHC 
Class I was responsible for the presentation of endogenously expressed 
proteins, while MHC Class II was responsible for the presentation of peptides 
acquired from exogenous sources, i.e. those eaten by phagocytic macrophages 
and dendritic cells. This delineation was questioned however, when it was 
observed that antigens from transplanted tumors were somehow being presented 
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by host APCs for the generation of CTLs (1). This phenomenon was eventually 
discovered to be brought about through crosspresentation.  
Crosspresentation (XPT) is the process wherein exogenous antigen is 
taken up by antigen presenting cells (APCs) to be processed and presented on 
MHC Class I molecules. In vivo, the main APCs that are capable of XPT are the 
dendritic cells (DC) (2-4) , though macrophages (5, 6) and more recently other 
cell types, have been demonstrated to have this ability (7-12).  
Besides the original case of transplant rejection, it turns out that XPT has 
an important role to play in the adaptive immune response. Naïve T cells are 
mainly localized in the lymphoid tissues (13), and rely on incoming APCs for 
activation. XPT allows antigen in the peripheral tissues to reach these T cells via 
migrating APCs. DCs, through XPT, can present viral antigen to CD8+ T cells, 
even though the DCs themselves are not infected (14). Presentation of tumor 
antigens is another important role (15). On the flipside, XPT has also been 
implicated in the initiation of autoimmunity, through the presentation of self 
antigens (16, 17). Islet dendritic cells are able acquire antigen from β-cells and 
initiate diabetogenic CD4+ and CD8+ T cell responses. 
B. Specialized Antigen Presenting Cells 
While many cells that are able to take up antigen has been shown to cross 
present, it is the dendritic cell that is the most efficient in this activity (3, 4). Of the 
various dendritic cell subtypes in the mouse, the CD8+ dendritic cell is the most 
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capable of XPTing many antigens(18-20). These cells normally reside in the 
spleen and lymph nodes. Meanwhile, in the periphery, the CD8+ CD103+ 
migratory DCs share similar qualities.  Why these DC subtypes are most 
specialized to crosspresent has been under intensive study.  
One of the characteristics that CD8+ DCs have is their expression of 
Clec9A. Clec9A is a cell surface receptor that recognizes F-actin in dead and 
dying cells (21). This receptor allows the DC to engulf cellular debris more 
efficiently, and also directs engulfed material to endosomes that promote XPT 
(22). CD8+ DCs also express higher amounts of MHC-I related presentation 
genes, such as components of the peptide loading complex (TAP1, TAP2, 
Calnexin, Calreticulin, ERp57) as well as proteases known to trim MHC-I 
destined peptides (ERAP1) (23). CD8+ DCs can also regulate endosomal pH via 
Nox2 (24), which limits antigen degradation and preserves them for presentation. 
Conversely, CD8+ DCs also express lower amounts of genes that can 
compromise XPT. For instance, these cells express lower levels of Siglec-G, a 
lectin whose activation deactivates NOX2, thus promoting excessive antigen 
degradation (25). 
C. Pathways of Crosspresentation 
The ability of antigen presenting cells to XPT was soon discovered to be 
more complex than it seemed. XPT shared key players with the Classical Class I 
pathway, but it also shared key steps with the MHC Class II pathway. The degree 
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of contribution by the Classical Class I and the Class II pathways differed 
depending on the type of antigen given to cells. This section attempts to 
subdivide the pathways of crosspresentation into 3 general classes – the 
phagosome to cytosol to ER (P2C2E), the phagosome to cytosol to phagosome 
(P2C2P) and the vacuolar pathways. Recent advances in the field however, 
indicate that there might be novel pathways still waiting to be characterized.  
i. The Classical MHC Class I pathway 
Before discussing the pathways of XPT, it is important to detail the steps 
in the Classical Pathway of Class I presentation (26) (Figure 1). XPT shares 
numerous key players with the Classical Pathway such as the proteasome and 
TAP1. The known pathways of XPT can be roughly subdivided on how much 
they overlap with the Classical Pathway. Furthermore, for several antigens, the 
pathway of XPT that overlaps most with the Classical Pathway, particularly the 
requirement for proteasomal processing of antigen, seem to have the biggest 
contribution to the generated immune response (27). 
Cellular proteins constantly undergo degradation as part of the normal 
catabolism of cells. These proteins are ubiquitinated and are hydrolyzed by the 
cytosolic proteasome to generate oligopeptides around 8-11 amino acids long 
(28). Most of these peptides are further degraded into amino acids by cytosolic 
peptidases (29). However, some peptides enter the endoplasmic reticulum (ER) 
through the transporter associated with antigen processing (TAP).  
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In the same compartment, newly synthesized MHC-I molecules associate 
with the peptide loading complex (PLC) which includes chaperone proteins such 
as Calnexin and Tapasin (30). These chaperones promote proper folding of free 
MHC heavy chains and facilitate β2m binding. Through association with the 
peptide loading complex (PLC), these now peptide receptive MHC Class I 
molecules are stabilized in the ER and can then accept peptides coming through 
the TAP transporter. In some cases, peptides that reach the ER are a bit too long 
– these peptides are trimmed by the ER resident protease ERAP1 prior to Class I 
loading (31, 32). Peptide-loaded MHC Class I molecules are freed from the PLC, 
and are shuttled to the cell surface for presentation. 
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Figure 1. Classical class I antigen presentation.  
Figure 1. Classical class I antigen presentation.  The classical pathway 
monitors the self-proteins and foreign proteins that are synthesized by cells. 
Expressed proteins destined for degradation are  conjugated with ubiquitin 
and then  degraded by proteasomes. Long peptides undergo trimming by 
cytosolic peptidases.  A fraction of peptides are translocated into the lumen 
of the ER via TAP. Some long peptides undergo trimming in the ER by ERAP. 
Newly synthesized MHC-I molecules associate first with the chaperone 
calnexin and then, via Tpn, with TAP in the PLC. After  binding TAP-
transported peptide, the MHC class I:peptide complexes are  transported 
through the secretory pathway to the plasma membrane, where they are 
presented to CD8
+
 cytotoxic T cells. Abbreviations: ER, endoplasmic reticulum; 
ERAP, ER aminopeptidase; ERGIC, ER-Golgi intermediate compartment; 
PLC, peptide loading complex; TAP, transporter associated with antigen 
processing, Tpn, tapasin. This figure was taken from a previous publication 
(Cruz, Colbert et al. 2017) 
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ii. The Phagosome – Cytosol - ER pathway 
The intrinsic link between the Classical Class I and the XPT pathways can 
be traced to the observation that a number of exogenously derived antigens were 
dependent on cytosolic cellular components for presentation. The presentation of 
ovalbumin-coated beads for instance, could be disrupted using inhibitors of the 
proteasome (33). The absence of TAP also abrogated XPT (33). What these 
data implied was that exogenous antigen was being transferred to the cytosol, 
and thereafter can follow the same steps that occur in the Classical Pathway. 
Further experiments have confirmed this transfer. The ribosome inactivator 
Gelonin, when given to dendritic cells, was able to cause cell death (33, 34). The 
same occurred with exogenous cytochrome c (35). These proteins caused cell 
death through interactions with cytosolic cellular components. Exogenously given 
horse radish peroxidase has been found active in cytosolic fractions (36). 
Exogenous β-lactamase was able to cleave cytosolic fluorescent substrates 
when given to DCs (37). While still under intense study, the transport of 
phagosomal components into the cytosol has been attributed to translocation 
channels recruited to the phagosome such as Sec61 (38). Another hypothesized 
mechanism of transfer is phagosomal  membrane disruption (39). 
  Thus, for a variety of antigens, the XPT pathway is no different to the 
Classical Pathway after a prior phagosome-to-cytosol step (Figure 2). 
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Figure 2. Cross-presentation, phagosome-to-cytosol pathway. 
Figure 2. Cross-presentation, phagosome-to-cytosol pathway.  For 
cross-presentation, exogenous antigen is internalized via pinocytosis, 
receptor-mediated endocytosis, or phagocytosis.  Components of the PLC 
traffic to the endocytic compartment through a mechanism involving Sec 22b. 
 MHC-I molecules may also traffic to endosomes from the plasma membrane 
(in part via a Rab11a and SNAP-23 mechanism) or from the ER (potentially by 
way of CD74 or another mechanism).  Antigen within the phagosome 
escapes to the cytosol either by membrane disruption or through an ERAD-
like translocation (green).  Antigen is then conjugated with ubiquitin and 
degraded by the proteasome.  Peptides are then transported by TAP into the 
ER (red lines) or back into the endocytic compartment (blue lines).  Long 
peptides in the ER can be further trimmed by ERAP (pink), whereas those in 
the endosome can be trimmed by IRAP (blue-green) before binding MHC-I. 
The peptide-MHC I complexes are then exported to the plasma membrane. 
Dashed lines indicate steps in the pathway that are not fully understood. 
Abbreviations: ER, endoplasmic reticulum; ERAP, ER aminopeptidase; 
ERGIC, ER-Golgi intermediate compartment; IRAP, insulin-regulated 
aminopeptidase; NOX2, NADPH oxidase 2; PLC, peptide loading complex; 
TAP, transporter associated with antigen processing; Tpn, tapasin. This figure 
was taken from a previous publication (Cruz, Colbert et al. 2017). 
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iii. The Phagosome – Cytosol – Phagosome pathway 
A layer of complexity was added to the phagosome to cytosol pathway 
when it was found that TAP was also recruited to some phagosomes (40). 
Phagosomal TAP was functional, and could mediate transport of peptides into 
purified phagosomes for Class I loading (41). Other novel transporters have also 
been reported to exist, as some peptides could be transported into phagosomes 
in the absence of TAP (42). When DCs were incubated with soluble US6, a viral 
inhibitor of TAP1, XPT of soluble ova was abrogated. This was due to the 
inactivation of TAP within the endosome itself, preventing re-entry of peptides 
(41). Moreover, members of the peptide loading complex (Tapasin, Calreticulin, 
Erp57) were found in the endosomes, providing the machinery required for Class 
I stabilization and loading.  
Further evidence of this phagosome-cytosol-phagosome route has been 
shown by the finding that several antigens, such as ova coated beads, required 
the Insulin-Regulated Aminopeptidase (IRAP) for optimal XPT (43-45). IRAP was 
localized in endosomal compartments, and functioned similarly to ERAP – 
trimming peptides to the correct length. Knockout of IRAP caused around a 50% 
decrease in ova bead XPT, similar to ERAP deficiency, and double knockout 
cells had a more severe phenotype than single knockouts of either genes.  
Collectively, these data suggested that phagosomes contained most if not 
all the necessary machinery to load MHC Class I. While the studied antigens still 
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required entry into the cytosol (presumably for proteasomal processing), the 
proteasomally generated antigen peptides could instead go back into the 
phagosome for Class I loading instead of heading through the ER. (Figure 2, blue 
lines) 
iv. The Vacuolar pathway 
This capability of certain phagosomes to recruit the Class I loading 
machinery became all the more apparent when it was observed that certain 
antigens, particularly bacteria (46, 47), did not require a cytosolic step in order to 
be presented. For some studies, XPT of this antigen was found to be brefeldin A 
and cycloheximide resistant, suggesting that presentation did not make use of 
newly synthesized MHC Class I molecules in the ER.  Bacterial antigens were 
also presented in TAP knockout APCs, and were resistant to proteasome 
inhibitors – indicating that antigen processing was also occurring in a self-
contained phagosomal environment. Since then, a variety of antigens, including 
polymer beads and cell associated antigen, have been found to at least be 
presented in part via this ‘vacuolar pathway‘ (27). 
In the vacuolar pathway, phagosomal proteases, particularly Cathepsin S, 
were responsible for generating the correct MHC-I peptide within the phagosome 
(27, 48-50). These proteases were able to generate the correct length of peptide, 
bypassing the need for the cytosolic proteasome and accessory trimming.  
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Phagosomal MHC Class I was then loaded with the peptides, and shuttled to the 
surface (Figure 3). 
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Figure 3. Cross-presentation, vacuolar pathway. 
Figure 3. Cross-presentation, vacuolar pathway.  Exogenous antigen is 
internalized via phagocytosis, pinocytosis, or receptor-mediated endocytosis. 
 Antigen is cleaved by proteases within the endocytic compartment (primarily 
by cathepsins) and can be further trimmed by IRAP.  MHC-I molecules are 
recruited either from the plasma membrane (blue lines) or from ER (red lines), 
presumably through similar mechanisms as in the P2C pathway.  Peptide is 
loaded onto MHC-I in the endosome,  and the complexes are then presented 
at the plasma membrane. Dashed lines indicate steps in the pathway that are 
not fully understood. Abbreviations: ERGIC, Endoplasmic reticulum--Golgi 
intermediate compartment; IRAP, insulin-regulated aminopeptidase.  This 
figure was taken from a previous publication (Cruz, Colbert et al. 2017). 
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D. Unanswered questions 
Throughout the years, a lot of progress has been made in characterizing 
XPT, though several questions remain. Dendritic cells have been shown to be 
specialized in preserving antigen and transferring it to the cytosol, but how this 
transfer occurs is unclear. Both XPT and the Class II pathway share the step of 
antigen internalization, but when or if these pathways diverge is still under study. 
While XPT and the Classical pathway share several key players such as the 
proteasome, new data suggest that the overlap between them is not as thorough 
as previously thought. 
i. How is antigen transferred to the cytosol? 
Notwithstanding the vacuolar pathway, the dependence of the majority of 
antigens on proteasomal processing implies that phagosome to cytosol transfer 
is a critical step in XPT. However, the mechanism of this transfer is poorly 
understood. Because phagosomes have been shown to acquire ER components, 
it has been proposed that antigens in the phagosome shuttle into the cytosol 
through an ER-associated degradation (ERAD)-like pathway (51). ERAD is the 
mechanism of how misfolded proteins escape the ER to be degraded by the 
cytosolic proteasome (52). These proteins are ubiquitinated and then transported 
by a complex including the ATPase p97 through an ER channel. The Sec61 
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translocon has been proposed to be this channel (38, 53), but other candidates 
such as Derlin or Hrd1 have also been put forward (52, 54, 55).  
On the other hand, because several proteins have been shown to undergo 
phagosome to cytosol transfer intact (33-35), other mechanisms besides ERAD 
may play a role, as ERAD normally involves ubiquitination and denaturation of 
target proteins. Perhaps phagosome disruption might be one such mechanism. It 
has been shown that large particles like silica crystals can cause phagosomal 
membrane disruption in macrophages, releasing the vacuole’s contents into the 
cytoplasm (39). Nevertheless, proteins in the phagosome may be denatured and 
chaperoned into the cytosol, where they can renature (56). This does not explain 
however, how non-proteins such as dextrans can also undergo cytosolic transfer 
(34). 
ii. Which compartment does crosspresentation take place? 
Another question is if there is a specialized phagosomal/endosomal 
compartment dedicated to XPT. In the MHC Class II pathway, antigen loading on 
Class II molecules occurs in the MHC Class II Compartment (MIIC), which 
contains antigen processing proteases, the Class II molecule, its associated 
Invariant Chain / Class II-associated invariant chain peptide (CLIP), and the 
peptide editing chaperones H2-DM and H2-DO (57, 58). Are there counter parts 
for XPT? Furthermore, the contrasting characteristics of the phagosome to 
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cytosol and vacuolar pathways adds another layer of complexity. What makes an 
antigen go through either? 
The transport of intact, bioactive proteins from the phagosome to the 
cytosol suggests that this occurs in a relatively early phagosome, wherein the 
conditions for sufficient antigen degradation have not yet been met. This 
hypothesis is supported by the finding that Sec61, a proposed channel that 
mediates this transfer, colocalizes with the antigen in early endocytic (Rab5+) 
compartments (38). Sec22b, proposed to transport the PLC from the ER to the 
phagosome, begins to be recruited to the phagosome within 15 minutes of 
phagocytosis (59). TAP1 and IRAP1 colocalize to these early vesicles as well 
(43, 60, 61). Several cell surface receptors implicated in XPT, such as Clec9a 
and the mannose receptor, directs antigen they bind to EEA1+ / Rab5+ vesicles 
(22, 62).  
In contrast, antigens that go through the vacuolar pathway must be 
completely processed within the phagosome, suggesting that they are loaded 
onto MHC Class I in relatively late/mature phagosomes. Indeed, several studies  
show that targeting antigen to Dec205 or to TLR2 also promotes XPT (63, 64). 
These target the antigen to late endosomes (Lamp1+ Rab7+). In the case of 
TLR2, antigen presentation is shown to be TAP independent. When soluble ova 
is given to DCs for presentation, staining with the SIINFEKL – H2-Kb specific 
antibody 25D1.16 shows that peptide loading occurs in both early and late 
compartments (65) . Elucidating the requirements for a particular antigen to 
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undertake the P2C vs the vacuolar pathway is of increasing interest. As the two 
pathways make use of different proteases to process the antigen, it is 
conceivable that differences would arise in the MHC Class I peptides they 
generate. This in turn can lead to the development of different immunodominant 
epitopes and the corresponding CD8+ T cell hierarchy. In a viral infection 
situation for instance, infected cells would mostly generate Class I peptides 
through the Classical Pathway. This being the case, efficient vaccine design 
would probably require targeting the antigen to the P2C pathway in DCs, as 
opposed to the vacuolar pathway, to better match with the target cells the T cells 
will encounter. 
iii. Where does phagosomal Class I come from? 
While XPT along the P2C route is able to make use of newly synthesized 
MHC-I in the ER, the source of MHC-I for the phagosomal pathways of XPT is 
currently under intense study. Internalization of cell surface MHC-I along with the 
antigen is one proposed route (65-69). The cytoplasmic tail of MHC Class I 
contains a conserved tyrosine that controls its recycling, and mutation of this 
amino acid decreased localization of MHC-I in endolysosomal compartments 
(66). This mutation, as well as deletion of Class I exon 7, was subsequently 
shown to decrease MHC-I internalization in DCs as well as XPT of soluble 
ovalbumin (65). 
17 
 
Phagosomal MHC Class I has also been proposed to be sourced 
internally rather than from the cell surface. Invariant chain (CD74), responsible 
for trafficking MHC Class II from the ER-golgi to late endosomal compartments, 
has been also shown to traffic Class I (70). Splenic derived DCs from CD74 KO 
mice were defective in XPT of soluble ovalbumin. However, different forms of 
antigen, such as polymer bead ova, were shown to be independent of CD74 (27). 
Recently, it has been proposed that APCs contain an internal pool of MHC 
Class I that is recruited to antigen containing phagosomes (71). The Rab 
GTPase Rab11a, implicated in MHC Class I recycling, supplies a specialized 
endosomal recycling compartment (ERC) with MHC from the surface. Once the 
APC internalizes antigen containing TLR ligands, MyD88 dependent signaling 
from the antigen containing phagosome triggers recruitment of MHC Class I 
containing vesicles from the ERC. Fusion of these vesicles with the phagosome 
brings the MHC in proximity of antigen derived peptides, for loading and XPT. 
iv. What is the relationship between the XPT and Class II 
Pathways? 
A big conundrum in the field of XPT is its relationship with the Class II 
pathway. While both pathways involve presentation of exogenous antigen, there 
are several divergences that occur even from the initial step of antigen 
acquisition. For instance, while both pathways are efficient in presenting 
particulate and cell associated antigens, soluble antigen is a particularly poor 
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source for XPT (5, 72). The phagosome to cytosol pathway of XPT involves the 
release of antigen into the cytosol. However, antigen processing for MHC Class II 
loading occurs in late endosomes/phagosomes. Thus, are the XPT and Class II 
pathways in competition for antigen? It has also been observed that dendritic 
cells have mechanisms to dampen endosomal degradative capability, allowing 
persistence of antigen for XPT. One example of which is the neutralization of 
endosomal pH by Nox2 (73).  On the other hand, several endosomal proteases, 
such as Cathepsin B (74-78), are activated by low pH, and these same proteases 
have been shown to generate peptides destined for Class II presentation. 
The vacuolar pathway of XPT is similar to the Class II pathway in that antigen 
processing and loading into MHC molecules occurs in a self-contained 
phagosome. They also share key proteases such as Cathepsin S, which 
processes antigen for XPT (27, 48-50) and degrades invariant chain for Class II 
presentation (74, 76). A still unanswered question is what makes an antigen go 
through the vacuolar vs the P2C (P2C2E/P2C2P) pathway. Cell associated 
antigen as well as polymer bead encapsulated ova undergo XPT using both P2C 
and vacuolar pathways (27) while iron oxide bound antigen seems to be 
restricted to P2C. Perhaps the presence of pathogen or damage associated 
molecular patterns (PAMPS or DAMPS) is the key. Bacterial antigens have been 
mostly associated with the vacuolar pathway (46, 47) . Moreover, the presence of 
TLR ligands on beads causes the recruitment of both MHC Class I and II to the 
bead containing phagosomes (71, 79). These PAMPS/DAMPS might be 
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triggering mechanisms that divert internalized antigen to degradative lysosomes 
(where pathogens are destroyed) rather than allow their release into the cytosol. 
Thus, the vacuolar pathway is utilized to allow XPT from these cytosol (more 
specifically, proteasome) inaccessible antigens.  
E. The rationale for a genomewide siRNA screen for 
crosspresentation  
Because of the several gaps in our understanding of the various XPT 
pathways, we have chosen to develop and utilize a forward genetic screen to 
identify genes involved in XPT. We hoped to do this by using a mouse 
genomewide siRNA library to look for such genes in an unbiased manner. The 
development of this screen as well as its results are discussed in this chapter. 
II. Materials and Methods 
A. Cell Lines and Culture Conditions 
i. Media 
Cells were maintained in Hybridoma Culture Media (HCM) composed of 
RPMI 1640, 10% FCS, 1X HEPES, 1X non-essential amino acids, 1X Antibiotic-
antimycotic, 1X L-glutamine and 54 uM 2-mercaptoethanol (Sigma). All 100x 
reagents were purchased from Gibco (Invitrogen, Thermo Scientific). 
For some experiments, complete DMEM (cDMEM) media was used. cDMEM is 
composed of all HCM supplements except 2-mercaptoethanol. The rationale for 
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the use of DMEM is its lack of glutathione, which is a reducing agent present in 
RPMI. Several experiments necessitated the need for reducing agent free 
environments. 
ii. DC3.2 
DC3.2 is one of the dendritic cell clones isolated from the work of Z.Shen 
& K.L.Rock (2). This clone was chosen as it has high levels of MHC Class I and 
Class II and gene silencing with siRNA worked well in this cell. In addition, these 
cells can be readily transduced with lentivirus harboring eukaryotic expression 
vectors. 
iii. DC3.2R 
DC3.2R is a variant of the DC3.2 cell line transduced with a lentiviral 
construct containing Renilla luciferase. The Thymidine Kinase – Renilla 
Luciferase insert from plasmid pRL-Tk (Promega) was PCR amplified and 
inserted into the lentiviral vector pCDH1-CMV-MCS-EF1-Puro (System 
Biosciences). 
DC3.2R was chosen because it coincidentally had very good crosspresentation 
and Class II presentation abilities as compared to other DC clones. 
iv. Luciferase expressing T cell Hybridomas (RF33-Luc, and 
MF2-Luc) 
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The RF33.70 cell line is a CD8+ T cell hybridoma that recognizes the ova 
peptide SIINFEKL on H2-Kb (80). MF2.2D9 is a CD4+ T cell hybridoma that 
recognizes the ova peptide Ova258-276 on I-Ab  (2).  
The T cell hybridomas were transduced with lentivirus containing NFAT-
Luciferase. The NFAT-Luciferase insert from plasmid pGL3-NFAT luciferase (A 
gift from Jerry Crabtree, Addgene plasmid #17870) (81) was PCR amplified and 
inserted into pCDH1-CMV-SV40-Bsd. This backbone vector is a modification of 
pCDH1-CMV-MCS-EF1-Puro (System Biosciences) wherein the EF1-Puro region 
was replaced with the blasticidin resistance gene under the SV40 promoter. 
Lentiviral infection was performed according to listed protocol below.  
B. Lentiviral transduction of Dendritic Cell Lines 
Lentivirus was produced by transfecting HEK-293T (ATCC) cells with the 
viral construct along with equimolar amounts of the plasmids Delta8.9 and VSVg 
(gifts from Dr. Eicke Latz, UMASS Medical School). Transfection conditions were 
done according to Lipofectamine 2000 protocol (Invitrogen). After 24 hours post 
transfection, cell culture media was replaced. The viral supernatant at 48 hours 
was collected and filtered through a 0.45 µm syringe filter. 1x105 DC3.2 cells 
were seeded in 6 well plates. The next day, media was removed and replaced 
with 1:1 mix of viral supernatant and HCM with 5 µg/ml polybrene (Sigma-
Aldrich). After 24 hours, cell media was replaced and after 48 hours post 
infection, 5 µg/ml puromycin/blasticidin (depending on vector) was added. Cells 
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were maintained in antibiotic media for at least two weeks, replacing media with 
fresh antibiotic every 2 days. 
 
C. siRNA transfections 
The siRNA used were SiGenome smartpools purchased from 
Dharmacon/GE. To transfect dendritic cell lines, the protocol for Lipofectamine 
RNAiMax (Invitrogen) was followed with the following conditions. Each well of a 
384 well plate was seeded with a mixture containing 0.2 µl of RNAiMax, 6.8 µl of 
1X siRNA buffer (Dharmacon/GE) and 3 µl of 0.5 µM siRNA. The mixture was 
incubated for 20 mins at room temperature. Then, 20 µl of dendritic cells (total of 
2.5x103) in RPMI 1640 with 15% FCS were added. The plate was spun down at 
200xg for 1 minute and incubated for 48 hours prior to assays.  
D. Antigen Presentation Assay 
i. Biomag-ova beads 
Biomag-ova beads are magnetic particles (Iron oxide) covalently 
conjugated to ovalbumin.  
BioMag Amine and BioMagPlus Amine Protein Coupling Kit were 
purchased from Bangs Laboratories. Chicken ovalbumin was purchased from 
Sigma-Aldrich. Protein conjugation was performed using the glutaraldehyde 
method according to bead manufacturer instructions. Briefly, beads were washed 
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in pyridine buffer and activated with 5% glutaraldehyde for 4 hours. The beads 
were then washed and incubated with 5 mg/ml ovalbumin dissolved in pyridine 
buffer overnight. Beads were extensively washed and resuspended in PBS. Ova 
concentration on the beads were measured using absorbance at 280 nm of pre 
and post coupling solutions. 
ii. Protocol for XPT and Class II Presentation assays 
To the transfected dendritic cells, biomag-ova was added along with a 1:1 
(DC:T cell) number of luciferase expressing reporter T cells. We assumed 1x104 
DCs were on the wells after 48 hours of transfection. For the genomewide siRNA 
screen, the concentration used for the XPT assay was 20 µg/ml ova (1 µg of ova 
in 50 µl total volume of the well). For the Class II assay, the concentration was 2 
µg/ml ova. After overnight incubation, luciferase expression by the T cells was 
measured using Oneglo reagent (Promega) according to manufacturer 
instructions. The luminometer used was an Envision (Perkin Elmer) equipped 
with ultra-sensitive luminescence module.  
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III. Results  
A. The Dharmacon Mouse Genome siRNA Library 
We performed the screen in collaboration with the Institute for Chemistry 
and Cell Biology Screening Facility (ICCB-L) at Harvard Medical School. We 
utilized Dharmacon siGenome siRNA library plates containing 20,552 siRNA 
wells. Of these, 719 were targeted against mouse Kinases and phosphatases, 
474 against GPCRs and the remainder for the rest of the genome. The library 
was composed of siRNA pools, with 4 different siRNA sequences targeting the 
same gene mixed in a single well. This increased the likelihood of gene 
knockdown, by targeting different regions of the mRNA. 
The siRNA library was reverse transfected into dendritic cells in 384 well 
plates. Each plate also contained controls containing H2-Ab or β2m siRNA using 
lipofectamine RNAiMax. 
B. DC3.2R as antigen presenting cells 
Before proceeding with the siRNA screen, our first task was to choose the 
appropriate antigen presenting cell for our assay. For this we chose a variant of 
the dendritic cell line DC3.2 (2). We have chosen to go through the cell line route 
as opposed to using primary cells as isolation of dendritic cells from mice is 
technically difficult and results in poor yields. Moreover, the isolated cells are of a 
mixed population, and various dendritic cell subsets have been reported to have 
differing crosspresentation abilities (23). Generation of large amounts of DCs 
25 
 
from the bone marrow is possible through GM-CSF or Flt3 ligand (82), though 
these only last for a week (requiring multiple preps that can increase variability) 
and are not amenable to siRNA transfection (Cruz F, Rock K, unpublished data). 
 DC3.2 was chosen among the various clones generated in the previous 
work because this clone retained high amounts of MHC Class II, which we would 
be using as a counter screen for XPT.  
DC3.2 was lentivirally transduced to express Renilla luciferase under a 
thymidine kinase promoter to create a new cell called DC3.2R. This was initially 
done in order to incorporate a viability assay along our siRNA screen. The 
rationale was that healthy, living cells would express Renilla luciferase 
commensurate to cell number and viability, and this can be correlated with T cell 
activity (discussed below). This would have allowed us to screen out genes that 
affected XPT nonspecifically, by disrupting normal cellular metabolism.  
However, during the optimization of the siRNA screen, we found that 
incorporation of this viability screen was not technically feasible. First, the siRNA 
screen was designed to have a 48 hour knockout period. When siRNA against 
several housekeeping genes was tested as positive controls, the knockdowns did 
not alter renilla luciferase signal significantly at 48 hours (Cruz F, Rock K, 
unpublished data). Moreover, the screen was to be done in 384 well plates, 
which greatly limited the volumes we could manipulate. Adding in the viability 
screen necessitated the dilution of reagents to keep the same volumes, and this 
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compromised the integrity of the T cell assay due to signal variability. Thus, we 
decided to drop this assay. 
Nevertheless, we proceeded to use the DC3.2R cells in the screen 
because it was found to have better XPT and Class II presentation abilities than 
its parental cell.  
C. Biomag-ova as particulate antigen 
We chose to use biomag-ova (ovalbumin covalently conjugated iron-oxide 
particles) as the antigen for the screen. This antigen was found to be TAP and 
proteasome dependent (33), suggesting that it goes through the phagosome to 
cytosol pathway. We chose to use this antigen as it was readily crosspresented 
by our various dendritic cell lines, that led to strong and consistent signals from 
the reporter T cells.  
Other antigens exist that are able to go through the vacuolar pathway as 
well (27). These include polymer encapsulated ova (PLGA-ova) and cell 
associated antigen. One concern in using this form of antigen was that if the P2C 
and vacuolar pathways had redundancy, then knockdown of genes that only 
affected one pathway would be missed by the screen. Furthermore, we were 
beset with technical difficulties in using them. In vitro, these forms of antigen 
were not crosspresented well by our cell lines and required steps not compatible 
with 384 well plates such as washing. These issues prevented us from utilizing 
them in a screen that required reproducibility and data reliability. 
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D. Reporter T cells (RF33-Luc and MF2-Luc) Compatible With 
High Throughput Assays 
The XPT ability of dendritic cells in vitro can be read in a number of ways. 
It can be read through the use of specific peptide-MHC antibodies such as 25-D1 
(83). A similar method was employed in a genome wide siRNA screen for Class 
II presentation, wherein antibodies against MHC II – peptide and MHC II-CLIP 
were employed (84). However, XPT in vitro is very inefficient as compared to the 
Class II and Classical Class I pathways, making surface detection of peptide-
MHC even from high amounts of antigen nearly undetectable (Cruz F, Rock K, 
unpublished data). For better sensitivity, readouts using T cell activity have been 
employed (2, 85). 
CD8+ T cell hybridomas exist for the detection of peptide-MHC I 
complexes in vitro (85, 86). Traditionally, target cell lysis, or T cell IL-2 production 
have been used to correlate with APC XPT. The level of sensitivity by these T 
cells far exceed that of peptide-MHC antibodies (83), making them ideal for 
detecting slight changes in surface peptide MHC levels. 
Nevertheless, due to the high throughput nature of siRNA screens, we had 
to modify these cell lines to make them feasible for use in our assays, typically 
done in bulk and contained within the confines of a 384 well plate. These 
limitations prevented the use of IL-2 detection and target killing (which require 
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washing steps for ELISA and reagent additions) as well as the use of IL-2 
dependent cell lines (85), which require radiometric analysis. 
Thus, we modified CD8 + (RF33.70) and CD4+ (MF2-2D9) T cell 
hybridomas (2, 85) by transducing them with a luciferase construct under the 
control of a minimal IL-2 promoter and 3x NFAT binding sites (now called Rf33-
Luc and MF2-Luc). T cell activation upon interaction with the appropriate peptide-
MHC activates NFAT, allowing expression of luciferase at levels that correspond 
to T cell signal. While reporter CD8+ T cells employing the same design but 
expressing β-galactosidase have been constructed (87), putting in luciferase in 
our reporter cells allowed us to take advantage of the greater speed and high 
throughput compatibility of luciferase’s luminescent read out as compared to 
other assays that employ colorimetry.  
As shown in (Figure 4), the generated reporter T cells were able to detect 
XPT and Class II presentation by APCs, and expressed luciferase in proportion 
to the amount of peptide MHC presented on the APC surface. 
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Figure 4. Reporter T cells express luciferase upon interaction with cognate MHC peptides 
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Figure 4. Reporter T cells express luciferase upon interaction with 
cognate MHC peptides. 
5 x 10
4
 RF33-Luc or MF2-Luc were incubated with the same number of APCs 
(DC2.4 cell line) as well as the indicated amounts of biomag-ova overnight. T 
cell luciferase activity was measured using Promega Oneglo reagent. Error bars 
indicate the standard deviation between triplicate wells. Data shown represents 
one experiment of >3. 
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E. Developing a Class II Counter Screen 
In designing a genome-wide siRNA screen, it was important to be able to 
determine if the phenotype observed was due to a gene specifically involved in 
the pathway studied, or was due to a pleiotropic effect commonly associated with 
housekeeping genes. For our assay, we have chosen to run a counter screen for 
the Class II pathway.  
In parallel to the XPT screen, we also screened the Class II pathway. The 
same transfected cells were instead exposed to reporter CD4+ T cells. If a gene 
being silenced was a housekeeping gene, and its knockdown caused cell death, 
then both XPT and Class II pathways would drop. This scheme also allowed us 
to determine if a particular gene was involved in a process shared by both XPT 
and the Class II pathway. Antigen internalization, as well as phagosomal 
degradation of proteins are among these shared processes. This permitted us to 
not only reduce the screen background but also uncover potential Class II 
specific genes. 
F. siRNA knockdowns effectively reduce XPT or Class II 
presentation 
When known MHC Class I related genes (β2m, TAP1) were knocked 
down with siRNA, XPT by DC3.2R of biomag-ova was selectively reduced 
(Figure 5). Conversely, when Class II related genes (I-Ab, H2-DMα) were 
silenced with siRNA, only Class II presentation was decreased. The decrease in 
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presentation was effectively measured by the luciferase expressing reporter T 
cells. Thus, we now had all the components necessary for the siRNA screen.  
We then performed the screen in following the workflow shown in (Figure 
6). 
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Figure 5. Knockdown of antigen presentation using sirna.
Figure 5. Knockdown of antigen presentation using sirna. 
2.5 x10
3
 DC3.2R cells were transfected with 50 nM sirna using Lipofectamine 
RNAiMax. After 48 hours, 1 x 10
4
 Rf33-Luc or Mf2-Luc cells were added along 
with 20 µg/ml (XPT) or 2 µg/ml (Class II) of biomag ova. After overnight 
incubation (~18 hours), Luciferase activity of the T cells were read using Oneglo 
reagent (Promega). Error bars indicate the standard deviation between triplicate 
wells. Data shown represents one experiment of >3. ns indicates p >0.05 in 
ANOVA. For xpt, all siRNA treatments except H2-DM have p< 0.05 against I-
Ab. For Class 2, all siRNA treatments except Tap1 have p< 0.05 against β2m. 
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Figure 6. Screen Workflow
Figure 6. Screen Workflow 
In each well of a 384 well plate, 2.5 x10
3
 DC3.2R cells were transfected with 50 nM sirna using Lipofectamine 
RNAiMax. This was done for 2 sets of triplicate plates. After 48 hours, 1 x 10
4
 Rf33-Luc or Mf2-Luc cells were 
added along with 20 µg/ml (XPT) or 2 µg/ml (Class II) of biomag ova. After overnight incubation (~18 hours), 
Luciferase activity of the T cells was read using Oneglo reagent (Promega). 
Transfect two sets of dendritic cells  
(3 replicates each) 
(~320 gene targets / plate) 
48 hours later: 
Add antigen and reporter T 
cells 
+18 hours: luciferase assay 
CD8 
CD4 
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G. Statistical Analysis for the Genome Wide Primary Screen 
To interpret the primary screen results, we have performed the statistical 
analysis as described below. All statistical analyses were performed in 
collaboration with Dr. Stephen Baker of UMASS Medical School. 
The entire mouse genome siRNA library consisted of 69 (384 well) plates 
and these were screened across several months. In order to account for 
experimental variation between library plates, we normalized plate values against 
internal controls. 
 Each library plate (done in triplicate) contained siRNA wells against H2-
Ab1 (beta chain of the Class II molecule I-A) and β2m. For each plate, the 
average T cell readouts from these controls were taken and were set to 100 
(percent signal from negative control) and 0 (positive control) respectively by 
generating a scaling factor using the equation: 
𝑠𝑐𝑎𝑙𝑖𝑛𝑔 𝑓𝑎𝑐𝑡𝑜𝑟 =
100
𝑛𝑒𝑔𝑎𝑡𝑖𝑣𝑒 𝑐𝑜𝑛𝑡𝑟𝑜𝑙 −  𝑝𝑜𝑠𝑖𝑡𝑖𝑣𝑒 𝑐𝑜𝑛𝑡𝑟𝑜𝑙
 
For the XPT screen this translates to: 
𝑠𝑐𝑎𝑙𝑖𝑛𝑔 𝑓𝑎𝑐𝑡𝑜𝑟 =
100
𝐼𝐴𝑏 −  𝛽2𝑚
 
* the controls are reversed during analysis of the Class II screen 
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The T cell readout from each siRNA well in a particular plate was then 
normalized to both positive and negative controls in the same plate. For the XPT 
screen, this was done in the equation: 
𝑠𝑐𝑎𝑙𝑒𝑑 𝑣𝑎l𝑢𝑒 = (𝐼𝐴𝑏 − 𝑠𝑖𝑟𝑛𝑎) ∗ 𝑠𝑐𝑎𝑙𝑖𝑛𝑔 𝑓𝑎𝑐𝑡𝑜𝑟 
This generated values that represent each siRNA’s position in relation to 
the negative and positive controls. Thus, when a variation in the experiment 
caused an increase or decrease in overall plate signal (which can be due to cell 
condition, plate reader variability, transfection and knockdown efficiency, etc), the 
relative value of the siRNA wells was preserved. This allowed comparison of 
values generated from multiple plates read over several days. 
 
All 69 plates of a single replicate were then merged, and z-scores for each 
gene were calculated: 
𝑧 𝑠𝑐𝑜𝑟𝑒 =
𝑠 − 𝑀
𝑀𝐴𝐷
 
where: 
s = scaled value of individual siRNA 
M = median of all experimental siRNA scaled values 
MAD = median absolute deviation 
where: 
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𝑀𝐴𝐷 =
𝑚𝑒𝑑𝑖𝑎𝑛(𝑠 − 𝑀)
0.6745
 
*0.6745 constant assuming a normal distribution 
The z score transformed the raw luminescence values into their distance 
to the genomic median. It was expected that majority of the genes would not hit 
XPT and would have z scores close to 0. Very low (negative values) represented 
genes that caused a huge knockdown in XPT, while very high values 
represented an augmentation in XPT. In genomewide screens, a threshold z-
score is chosen to limit the number of hits. Before that however, we needed to 
take into account experimental variability. 
 The siRNA plates were done in triplicate plates. To take into account 
variability among the plates, the following equation was applied: 
𝑡𝑠𝑡𝑎𝑡 =
𝑍𝑎𝑣𝑒
√(𝑍𝑠𝑑
2 /3)
 
where: 
𝑍𝑎𝑣𝑒 = 𝑎𝑣𝑒𝑟𝑎𝑔𝑒 𝑧 𝑠𝑐𝑜𝑟𝑒 𝑜𝑓 𝑎𝑛 𝑠𝑖𝑟𝑛𝑎 (𝑡𝑟𝑖𝑝𝑙𝑖𝑐𝑎𝑡𝑒𝑠) 
𝑍𝑠𝑑 = 𝑠𝑡𝑎𝑛𝑑𝑎𝑟𝑑 𝑑𝑒𝑣𝑖𝑎𝑡𝑖𝑜𝑛 𝑜𝑓 𝑡ℎ𝑒 𝑧 𝑠𝑐𝑜𝑟𝑒𝑠 𝑜𝑓 𝑎𝑛 𝑠𝑖𝑟𝑛𝑎 
 
 To determine the confidence level that a particular gene has of being a 
real hit, a T-distribution was then generated using the EXCEL equation: 
37 
 
𝑝 = 𝑇𝐷𝐼𝑆𝑇(𝐴𝐵𝑆(𝑡𝑠𝑡𝑎𝑡), 2,1) 
* 2 degrees of freedom, 1 tailed 
 
If a given gene had a good z score (in this case, very negative meaning a 
huge average knockdown in T cell signal), but was extremely variable between 
its triplicates (due to technical/human error), the variability brought down the tstat. 
This would have brought down its p value lowering the confidence that it was a 
real screen hit. 
 
For selecting primary screen crosspresentation hits, the following criteria was 
chosen: 
𝐶𝐷8 𝑠𝑐𝑎𝑙𝑒𝑑 𝑘𝑛𝑜𝑐𝑘𝑑𝑜𝑤𝑛 ≥ 50% 
This corresponds to a CD8 z-score = 0.5 
𝐶𝐷4 𝑠𝑐𝑎𝑙𝑒𝑑 𝑘𝑛𝑜𝑐𝑘𝑑𝑜𝑤𝑛 ≤ 0 
and 
𝑝 ≤ 0.02 
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H. Association of genes with available databases 
497 of the 20,552 screened genes (2.4%) passed the thresholds we set 
for the primary XPT screen. In order to limit the number of candidates for further 
study, a number of genes were selected for siRNA deconvolution (discussed 
below). Before this however, we screened the hits against publicly available 
literature and databases in order to determine which genes would be suitable for 
this analysis. 
i. Clustering and enrichment of hits via General Ontology 
One method used to analyze large scale gene datasets is to cluster them 
via functional annotation. Genes that clustered around the same pathways or had 
conserved domains/structures would likely have similar or complementary roles 
in XPT, therefore aiding in their characterization. Several tools such as DAVID 
(The Database for Annotation, Visualization and Integrated Discovery)(88) and 
the Panther (Protein Analysis Through Evolutionary Relationships) Classification 
System (89, 90) exist that allow  clustering of genes via common properties, such 
as involvement in the same cellular pathway. Once clustered, we wanted to see if 
certain gene subsets were being enriched by the screen. This was calculated by 
the above listed tools by comparing the proportion of the generated clusters 
within our gene set to their natural proportion in the whole mouse genome. 
When genes selectively affecting XPT were clustered according to cellular 
component / localization, significant enrichment of golgi and cilum localized 
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genes was observed (Table 1). When looked at more closely, these genes 
seemed to be involved in cytoskeleton and membrane/trafficking processes (Rab 
GTPases, EHD1, dynein, etc) (Table 2, Table 3). 
Concordant to this finding, when XPT selective genes were clustered 
according to their involvement with specific biological processes, we observed 
significant enrichment in genes involved in vesicle organization and organelle 
fusion (Table 4, Table 5, Table 6).  
Despite not being a category particularly enriched in the 
clustering/annotation process, we also looked for genes that were specifically 
localized in the endosomes and lysosomes, where the XPT and Class II 
pathways were likely to diverge. Several endo-lysosomal and vesicular 
components have been recently published to affect XPT. Among these were 
several Rab GTPases (discussed in later chapters), usually implicated in 
controlling vesicular transport (44, 67, 71, 91). While the Class II pathway was 
not specifically addressed in these studies, most of the proposed models seemed 
to indicate a role of these proteins in the specific trafficking of MHC Class I. Our 
primary screen also identified genes localized in the vesicles / endo-lysosomes 
(Table 7). How these affect XPT but not Class II would be an interesting field to 
study. 
40 
 
Table 1. Clustering of XPT selective hits via cellular component/localization 
Table 1. Clustering of XPT selective hits via cellular 
component/localization 
XPT selective hits were annotated using DAVID (https://david.ncifcrf.gov) using 
the specified categories. Count represents the number of genes that fall in each 
term and percentage represents its proportion in comparison to the whole gene 
list. P-values represent the probability that the given term is enriched within the 
gene list when compared to the whole mouse genome. Shown are categories 
with p values < 0.05. 
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Table 2. Golgi localized genes involved in XPT 
 
Table 2. Golgi localized genes involved in XPT 
Genes associated with the golgi apparatus, a subset of Table 1 
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Table 3. Cilium localized genes involved in XPT  
Table 3. Cilium localized genes involved in XPT 
Genes associated with the golgi apparatus, a subset of Table 1. 
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Table 4. Clustering of XPT selective hits via involvement with specific biological processes  
Table 4. Clustering of XPT selective hits via involvement with specific 
biological processes 
XPT selective hits were annotated using DAVID (https://david.ncifcrf.gov) using 
the specified categories. Count represents the number of genes that fall in each 
term and percentage represents its proportion in comparison to the whole gene 
list. P-values represent the probability that the given term is enriched within the 
gene list when compared to the whole mouse genome. Shown are categories 
with p values < 0.005. 
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Table 5. Genes associated with vesicle organization  
Table 5. Genes associated with vesicle organization 
List of genes associated with vesicle organization, a subset of Table 4. 
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Table 6. Genes associated with organelle fusion  
Table 6. Genes associated with organelle fusion 
List of genes associated with organelle fusion, a subset of Table 4. 
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Table 7. Screen Hits enriched in endosomes and lysosomes. 
Table 7. Screen Hits enriched in endosomes and lysosomes. 
Primary screen hits selective for crosspresentation were functionally annotated 
with DAVID (https://david.ncifcrf.gov). Tabulated are genes found in endosomes 
and lysosomes as characterized under the GOTERM_CC_DIRECT database 
(Gene Ontology Consortium, cellular component). 
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ii. Expression in immune cell subsets 
Another criterion we used to determine gene candidates was their 
expression in specific immune subsets. Dendritic cells have been shown to be 
specialized for XPT, and among the DCs, the CD8α+ (and CD103+) subsets were 
the ones with the most XPT potential. Studies have shown that CD8α+ DCs 
highly expressed genes involved in the Classical Class I Pathway such as ERAP 
and the members of the PLC (TAP1/2, Calnexin, Erp57, etc) (23). This subset 
also expressesed high amounts of Clec9a (92) and Nox2 complex components 
(24). Because of this, screen hits that were highly enriched in CD8α+ DCs were 
taken for further study. 
We matched our database with that of Immgen (93), which contained 
probe-based (Affymetrix) gene expression profiles of specific immune subsets. 
(Table 8) shows crosspresentation selective genes that were enriched in CD8α+ 
DCs from various tissues. 
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Table 8. Screen Hits enriched in CD8α+ Dendritic Cells. 
Table 8. Screen Hits enriched in CD8α+ Dendritic Cells. 
Primary screen hits for crosspresentation were matched with the Immgen 
database (Immgen.org). Standard z scores of the entire Immgen database were 
calculated using the database mean and standard deviation. P values from the 
generated T distribution of z scores were obtained and the gene list was filtered 
for genes that were positively enriched (z > 0) in any of the listed CD8α DC 
subsets. Tabulated are p values and highlighted are p < 0.05. *THY, thymic; 
MLN, mesenteric lymph node; SLN, skin draining lymph node; SPL, splenic 
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iii. Comparison with a published MHC Class II screen 
Neefjes et. al. has published a genomewide siRNA screen for human 
genes affecting Class II presentation (84). In their screen, they utilized antibodies 
specific for MHCII-CLIP peptide (CerCLIP antibody) as well as peptide bound 
MHCII (L243 antibody).  
In the Class II pathway, MHC Class II is trafficked by the invariant chain to 
late endosomes, wherein invariant chain is degraded into a remnant CLIP 
peptide that caps the MHC Class II molecule. Through the function of low pH as 
well as chaperones such as H2-DM and H2-DO, this CLIP peptide is replaced by 
peptides that derive from exogenous antigen taken up by the APC.  
The multidimensional approach employed in their screen allowed them to 
differentiate genes that affected general MHC Class II trafficking (which would 
decrease staining of cells by both antibodies) or those that had more specific 
effects, such as peptide loading and/or invariant chain processing (would likely 
increase staining of CerClip). 
We compared Class II pathway hits in our screen to the mouse orthologs 
of the published screen hits. Of the 262 candidate genes in the published work, 
43 of them were also hits in our Class II screen (with at least 50% knockdown in 
Class II presentation and a p value of < 0.05 for Class II presentation). These 
common hits are shown in (Table 9). 
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Table 9. Common hits with a previously published screen for Class II presentation  
Table 9. Common hits with a previously published screen for Class II 
presentation 
Shown are hits in our screen that had > 50% knockdown in Class II presentation 
as well as  p < 0.05 for the Class II pathway. These genes are mouse orthologs 
of genes that were previously published to affect Class II presentation in a 
human sirna screen (Paul, van den Hoorn et al. 2011).   
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However, several of these common hits also affected crosspresentation in 
our primary screen. This was expected as XPT and the Class II pathways shared 
the steps of phagocytosis as well as endosome/phagosome maturation. Of these 
hits, 7 genes were reliably selective for the Class II pathway and did not hit the 
crosspresentation pathway (with p < 0.05 for both pathways). These genes are 
shown in (Table 10). Many genes were not considered selective primarily due to 
the fact that they did not pass the statistical test for variability (p value). Thus, 
these 7 genes were probably an underestimation of the real hits. How these 
genes only selectively affect the Class II pathway would be interesting to study.  
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Table 10. Class II selective hits that are common with a previously published screen for Class II presentation. 
Table 10. Class II selective hits that are common with a previously 
published screen for Class II presentation. 
Shown are hits in our screen that had > 50% knockdown in Class II presentation 
as well as p < 0.05 for the Class II pathway. The genes also did not affect the 
crosspresentation pathway with p < 0.05. 
The human orthologs of these genes were previously published to affect Class 
II presentation in a human sirna screen (Paul, van den Hoorn et al. 2011).   
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I. siRNA Deconvolution 
Before proceeding with the characterization of the primary screen hits, we 
performed siRNA deconvolution. This process allowed us to determine if our 
primary screen phenotype was due to the knockout of the particular gene or was 
due to siRNA off target effects. 
 A particular siRNA can have sequence specific off target effects. The 
siRNA pathway generally requires a perfect match between the guide siRNA and 
its target to initiate Argonaute mediated mRNA cleavage (94), and siRNA 
libraries are constructed to generate guide sequences unique to target genes. 
However, a parallel pathway in the cell -  the miRNA pathway, mediates a similar 
knockdown of genes but do not require exact miRNA-target complementarity. In 
this pathway, complementarity between an inner “seed” sequence of the miRNA 
and its target is sufficient to mediate knockdown, while the miRNA flanking 
sequences are allowed some variability. Because of this, particular regions of an 
siRNA introduced into cells have a chance of mimicking miRNAs, thereby 
causing unintended knockdowns. Besides mimicking miRNAs, partial siRNA 
complementarity to nonspecific mRNA can decrease gene expression by 
blocking translation initiation. 
 Furthermore, siRNAs can also demonstrate sequence independent off-
target effects (94). Rather than binding to nonspecific mRNA, siRNA, particularly 
in high concentrations, can instead disrupt normal miRNA processes occurring 
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within cells. High concentrations of siRNA can displace miRNA from the RISC 
complex, or compete with miRNA trafficking and export factors (95) . The 
disruption of miRNA can have global effects on the cell, as they are utilized to 
regulate gene expression. Other sequence independent siRNA effects include 
the activation of immune sensors and increased cell stress. 
 In order to account for siRNA off-target effects, a selection of genes was 
subjected to siRNA deconvolution.  The siRNA smartpool used in the primary 
screen (composed of a mixture of 4 different siRNA oligos) was separated into its 
individual components. Cells were transfected separately with each of the 
individual oligos. Genes that had at least 2 different siRNAs recapitulating the 
phenotype (affected XPT but not Class II presentation) were picked for further 
study (Table 11). 
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Table 11. A selection of genes that passed siRNA deconvolution screening. 
Table 11. A selection of genes that passed siRNA deconvolution. 
Listed are genes with at least 2 individual sirna oligos causing a knockdown in 
crosspresentation but not Class II presentation. 
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IV. Discussion 
In this work, we have successfully developed and utilized a genomewide 
siRNA screen for genes that affected crosspresentation or the Class II pathway. 
A number of genes are currently undergoing characterization. 
From the entire annotated mouse genome, our primary screen has identified 
472 genes to be selectively involved in XPT based on the thresholds we have 
set. This was not an absolute number, as one can loosen the thresholds to 
identify additional genes. We had set the threshold to only pick genes that 
caused a large decrease (> 50%) in XPT. This was done to limit the number of 
genes to a more manageable number. Certainly, there could be genes relevant 
to XPT that do not cause such huge defects. Examples of these are certain 
proteases/peptidases that can have important but redundant effects. The 
specialized proteasome subunits (immunoproteasome & thymoproteasome) are 
an example. These subunits have been shown to critically influence antigen 
presentation and T cell development (96-98) but their lack or deficiency can be 
rescued by components of the constitutive proteasome.  
Several limitations affected the number of hits and the nature of the genes 
that we got from the screen. One of these was the nature of the antigen used for 
screening. XPT in vitro is a very inefficient process, as compared to Classical 
presentation in vitro or XPT in vivo. This inefficiency limited us to using magnetic 
bead conjugated ova, as this form of antigen was the most consistent in in vitro 
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experiments. Because of this, the screen was limited to the P2C pathway of XPT. 
On the other hand, this might have been a benefit as well, as using antigens that 
routed through multiple pathways (like cell associated antigen), might encounter 
redundancy. For instance, knockdown of cytosolic proteases (proteasome) might 
not greatly affect XPT of cell associated antigen if this antigen can alternatively 
be processed in the endosomes by Cathepsins.  
Besides limiting the nature of the antigen, the assay had to be constrained in 
384 well plates with a relatively short assay duration. The use of 384 well plates 
prevented media exchange or excessive additions of reagents. Thus, we could 
only work within 48 to 72 hours post siRNA transfection, to prevent media 
exhaustion or cell overgrowth. This meant that we could not extend the 
knockdown periods. Therefore, we could expect that genes important to XPT, but 
had long enough protein half lives might have been missed by the screen.  
The very small volumes in 384 well plates also meant that small variations in 
pipetting volume or even temperature could produce huge effects in well to well 
variability. In fact, we have experienced this as we observed a significant edge 
effect while optimizing the screen. We observed decreased XPT from wells near 
the edges of the 384 well plate regardless of siRNA. Edge effects in high 
throughput screens have been reported, and these effects were primarily brought 
about by temperature changes occurring on plate edges (99). The edges of the 
plate changed temperature more rapidly than the center, and this had effects on 
cell growth and settling distribution. We did our best to combat these pitfalls 
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through the use of robotics for pipetting as well as the use of special humidified 
plate chambers to normalize temperature. However, other factors could have 
affected our screen, causing several potential candidate genes to fail our 
threshold tests due to variability between its triplicate wells. 
Nevertheless, the candidate genes that did pass our strict thresholds that we 
chose to follow up on all recapitulated the phenotype when we repeated the 
experiments in our laboratory, using less constrained methods. These genes only 
affected XPT and not the Class II pathway, showing that our screen and method 
of picking gene candidates were robust. These genes are now being 
characterized by several members of our group.  
One cannot truly say that a particular gene is important to XPT based on an 
siRNA screen alone. In order to do so, the candidate genes need to be further 
characterized and their mechanism in relation to XPT established. One such 
gene, the Rab GTPase Rab39a, has been identified by the screen to affect XPT. 
The characterization of this gene – its nature, mechanism and relevance to XPT 
is the focus of the next chapter of this dissertation. 
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CHAPTER II: Rab39a Promotes Crosspresentation Through The Delivery Of 
ER-Golgi Components To The Nascent Phagosome 
 
I. Introduction 
A. Rationale for Rab39a 
Using a genome-wide siRNA screen for genes affecting the XPT and 
Class II pathways, we have identified Rab39a as having a potential and specific 
role. We were particularly interested in this candidate because the screen 
showed that its knockdown only affected XPT, but left Class II presentation 
intact. Published data (discussed in later sections) showed that Rab39a is 
localized in endosomes and phagosomes. XPT and the Class II pathway both 
acquire exogenous antigen similarly, and Rab39a might be able to shed light on 
how and when these pathways diverge.  Another interesting observation was that 
this gene is primarily expressed in the professional APCs, with the highest 
expressers being the CD8α+ dendritic cells (Immgen) (93). 
 
B. Role of vesicular trafficking and Rab GTPases 
The apparent divergence of antigen into the XPT and Class II pathways is 
still a mystery. The notion of phagosome to cytosol transfer of antigen, which is a 
requirement for several XPT antigens due to their requirement for proteasome 
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processing, seems detrimental to the Class II pathway. This is because Class II 
antigen processing and MHC Class II loading occurs within the phagosomes. Are 
some antigens routed to XPT while others are sent to the Class II pathway? If so, 
how and when? Are phagosomes segregated based on what internalization 
receptor is utilized for entry? Does kinetics and maturation state of the 
phagosome play a role, wherein early phagosomes are more suitable for XPT 
while later, more mature ones are used for Class II? 
The discovery of Rab39a as a selective hit for XPT led us to look into the 
role of Rab GTPases and vesicular trafficking. Rab proteins (ras gene from rat 
brain) are monomeric GTPases that serve as molecular switches that regulate 
trafficking, fusion and organization of membranes in eukaryotic cells (100). They 
exist in two forms, a GDP-bound ‘inactive’ form, and an ‘active’ form bound to 
GTP. Upon synthesis Rabs are in the inactive form, and are chaperoned by Rab 
escort proteins (REP) to geranylgeranyl transferase (GGT). This enzyme 
modifies the cytosolic tail of the Rab protein, allowing it to be membrane bound. 
Targeting to their cognate membranes is then mediated by Rab GDP dissociation 
inhibitors (GDI) and GDI displacement factors (GDF). Membrane bound inactive 
Rabs are then activated by guanine nucleotide exchange factors (GEF), 
switching the bound GDP for GTP. This activation causes a conformational 
change on the Rab protein, allowing it to bind specific effectors to mediate its 
function. Examples of these effectors include motor adaptors, that permit 
trafficking of Rab bound vesicles along the cytoskeletal track. Other effectors are 
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tethering proteins, that stabilize opposing membranes with t- and v- SNARES 
(SNAP (soluble NSF attachment protein) receptor) and prepare them for fusion. 
Once its work is done, Rab proteins are inactivated by GTPase activating 
proteins (GAP) – returning the Rab to its original GDP bound state for recycling. 
Recently, a variety of Rabs have been implicated in the regulation of XPT. 
Rab11a, first implicated in the recycling of MHC-I (69), has been shown to cause 
accumulation of Class I molecules in a distinct intracellular compartment (71). 
These Class I molecules are then shuttled to phagosomes containing TLR4 
ligands. It has been proposed that this intracellular pool can be the source of 
Class I molecules utilized by XPT, particularly during phagosomal loading in the 
phagosome-cytosol-phagosome and vacuolar pathways. A similar phenotype has 
been observed with Rab22a, wherein its knockdown caused a decrease in the 
recycling and intracellular pool of Class I (68). Rab3b/3c, identified in an siRNA 
screen of Rabs affecting XPT by DCs, has been proposed to be involved in 
exocytosis of recycled Class I (67). Rab14 positive endosomes have been 
associated with Insulin Responsive Aminopeptidase (IRAP), which trims peptides 
in the phagosomes. Rab27a regulates recruitment of NADPH oxidase (NOX2), to 
dendritic cell phagosomes. NOX2 modulates phagosomal pH and prevents 
extensive antigen degradation and loss, thereby increasing DC XPT capability 
(101). In Rab43 knockout mice, XPT of cell associated antigen is defective 
specifically in CD8α+ dendritic cells (91). This might be due to its role in 
Cathepsin D delivery, which can aid in peptide generation (102).  
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C. Background on Rab39a 
Rab39 was first described after having been isolated from a human 
dendritic cell cDNA library (103). It was found to colocalize with the golgi 
apparatus, and overexpression increased endocytosis by HeLa cells.   
Further advances in the field has shown that while Rab39 is conserved in most 
metazoans, there are in fact 2 isoforms (in this case, a Rab of similar protein 
sequence) of the gene in mouse and humans (104). Rab39a localizes at the 
periphery of Lamp2 positive vesicles, while Rab39b is golgi localized (105). 
Rab39a has been reported to bind Caspase-1 and mediate IL-1β release in 
thymocytes (106). It has also been shown to downregulate LPS-mediated 
autophagy by macrophages (105). Rab39b on the other hand, is involved in 
neurite morphology and has been linked to X-linked mental retardation (107). 
In the field of immunology, Rab39a has been shown to be utilized by the 
immune response against pathogens (102) as well as being utilized by the 
pathogens themselves (108). In macrophages fed with S.aureus or 
M.tuberculosis, Rab39a is recruited to late phagosomes (peaking at 1 hour post 
phagocytosis). Overexpression of the dominant negative form of Rab39a led to a 
decrease in phagosome staining by Lysotracker dye, implying that it plays a role 
in host defence through phagosome acidification. Chlamydia has been shown to 
recruit Rab39a to its inclusions (108). It has been proposed to mediate delivery of 
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multivesicular bodies and sphingolipids to the parasite inclusion to facilitate its 
growth. 
 Our work sheds light on a new role of Rab39a in the immune response. 
Here we show that Rab39a specifically promotes XPT, while having no effect on 
both the Classical Class I and the Class II pathways. We propose that Rab39a 
achieves this by facilitating transport of ER-golgi derived cargo to phagosomes. 
This cargo includes Sec22b, as well as components of the peptide-loading 
complex such as TAP and open forms of MHC-I. In accordance to published 
reports on Sec22b, this delivery also facilitates a downregulation in phagosomal 
antigen degradation (59), which can possibly aid in antigen persistence. An 
interesting finding of this work shows that Rab39a expression leads to an 
accumulation of peptide receptive MHC Class I molecules in the phagosome – 
possibly shedding a light on the source and nature of the Class I molecule used 
for XPT.  
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II. Materials and Methods 
A. Chapter I Protocols 
Parts of Chapter 2 utilized the same experiments as those in Chapter I. 
The detailed protocols for them can be found in that Chapter. Modifications of the 
protocols are detailed below. For reference, the protocols that can be found in 
Chapter 1 are: 
  
 
Cell lines and culture conditions 
 
Lentiviral transduction of Dendritic Cell 
Lines 
 
SiRNA transfections 
 
Antigen presentation assay 
 
 
B. Cell terminology 
Various cell lines have been used in this study. Cell creation and detailed 
cell properties are discussed in other sections of Materials and Methods. Here is 
a list of cells and a summary of their properties: 
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Cell name Property 
DC2.4 Dendritic cell line 
DC3.2 Dendritic cell line similar to DC2.4 but 
with high levels of MHC Class II 
DC3.2R DC3.2 cell line expressing Renilla 
Luciferase. Cloned for high XPT and 
Class II ability 
DC3.2-Rab39aKO DC3.2 cells where Rab39a was 
knocked out with CRISPR 
DC3.2-Rab39aKO-Rab39a A doxycycline inducible Rab39a 
construct was transduced into the 
knockout cells 
DC3.2-Rab39aKO-Rab39a-Ld H2-Ld was transduced in the above 
cell 
DC3.2-Rab39aKO-Rab39a(DN) A doxycycline inducible Rab39a 
dominant negative construct was 
transduced into the knockout cells 
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DC3.2-Rab39aKO-Rab39a(CA) A doxycycline inducible Rab39a 
constitutively active construct was 
transduced into the knockout cells 
RF33.70 CD8+ T cell hybridoma recognizing 
SIINFEKL on H2-Kb 
RF33-Luc RF33.70 that expresses Firefly 
luciferase upon activation via TCR 
MF2-2D9 CD4+ T cell hybridoma recognizing 
ISQAVHAAHAEINEAGR on I-Ab 
MF2-Luc MF2-2D9 that expresses Firefly 
luciferase upon activation via TCR 
12.64-Luc CD8+ T cell hybridoma recognizing the 
ASNENMETM peptide of the influenza 
peptide NP366. Expresses Firefly 
luciferase upon activation via TCR  
DC3.2 NSova DC3.2 cells transduced with a 
doxycycline inducible cytosolic 
ovalbumin 
DC3.2 UbS8L DC3.2 cells transduced with a 
doxycycline inducible SIINFEKL 
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conjugated to the C-terminus of 
Ubiquitin 
C. Additional cell lines used in this study 
i. DC3.2 NSova and DC3.2 UbS8L 
DC3.2 NSova is a variant of DC3.2 (see Chapter I) that expresses a non-
secreted form of ovalbumin upon induction with doxycycline. The gene for 
chicken ovalbumin (109) was amplified without the first 50 amino acids, replacing 
it with a methionine. The insert was put into the Age-I Mlu-I sites of pTRIPZ 
(Open Biosystems) for lentiviral production and transduction of DC3.2. pTRIPZ 
contains the tet on promoter system allowing dox inducible expression of cloned 
genes. 
DC3.2 UbS8L is another doxycycline inducible cell line. This line 
expresses the SIINFEKL peptide fused to the C-terminus of Ubiquitin. The 
Ubiquitin-S8L construct (110, 111) was PCR amplified and inserted into the 
above listed lentiviral vector.   
ii.  12.64-Luc T cell Hybridoma 
12.64 is a CD8+ T cell hybridoma recognizing the ASNENMETM peptide 
of the influenza peptide NP366 (86). This hybridoma was also transduced with 
the NFAT-Luciferase construct similarly to RF33-Luc and MF2-Luc (see Chapter 
I). The 12.64-luc cell was made by D. Farfan (96). 
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D. Antibodies  
The following antibodies were used: H2-Kb (Af6-88.5, BD biosciences) I-
A/I-E (M5/114.15.2, BD biosciences), Lamp1 (1d4B, Bd biosciences), Lamp2 
(abl-93, abcam) ovalbumin (ova-14, Sigma-Aldrich), mouse IgG1 anti HA-tag 
(6E2, Cell Signaling), rabbit anti HA-tag (C29F4, Cell Signaling), H2-Ld closed 
conformer (30-5-7s, Thermo Scientific) Sec22b (rabbit polyclonal, Synaptic 
Systems), TAP1 (B-8, Santa Cruz Biotech), Mouse anti actin (C-4, Santa Cruz) . 
The antibody for H2-Ld open conformers (64-3-7) was generated by Dr. Clifford 
Harding (Case Western Reserve University) and is a gift from Dr. Xiaoli Wang 
(Washington University, St Louis MO). Fluorescently labelled secondary 
antibodies (goat anti mouse IgG2a, goat anti mouse IgG2b, goat anti mouse 
IgG1, goat anti mouse IgG, Donkey anti rabbit IgG) were purchased from Thermo 
Scientific.  HRP conjugated secondary antibodies were purchased from Jackson 
Immunoresearch. 
E. Quantitative PCR 
After siRNA treatment of cells, total RNA was extracted using RNeasy 
Mini Kit (Qiagen) according to manufacturer instructions. Quantitative PCR was 
performed using Luna Universal One-Step RT-qPCR kit in a Bio-Rad CFX96 
cycler. HPRT was used as housekeeping control and relative expression were 
calculated using ΔΔCT method. The primers used were HPRT (5’-
AGGGATTTGAATCACGTTTG-3’ and 5’-TTTACTGGCAACATCAACAG-3’), 
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Rab39a (5’-CGCTTCAGATCAATAACTCG-3’ and 5’-
TGTCCCACCAGTAGAAATAC-3’) Rab39b (5’- 
GGATACAGCGGGTCAAGAGAGG -3’ and 5’- 
GTTGGTAATGTCAAATAAGAGAAGAC -3’). Primers for Rab39b were derived 
from a previous work (107). 
 
F. Antigen presentation assay 
The protocol antigen presentation can be found in Chapter I. Some 
experiments in this Chapter make use of different antigen concentrations and 
different forms of antigen. These are detailed within the figures. Detailed below 
are new forms of antigen we used in this Chapter, not found in Chapter I. 
 
i. Peptide beads 
Peptide beads are biomag beads conjugated to various peptides via a 
disulfide bond.  
All peptides were custom made to >98% purity (Genscript). For bead 
conjugation, biomag Amine beads were reacted with SPDP (succinimidyl 3-(2-
pyridyldithio)propionate) (Thermo Scientific) according to manufacturer 
instructions. 1 mg of lyophilized cysteine containing peptides were dissolved in 
DMSO and added 1:1 with PBS to SPDP-activated beads for overnight 
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incubation at room temperature. Peptide-bound beads were extensively washed 
with PBS. 
As a control, full length ovalbumin (Sigma-Aldrich) was also conjugated to 
biomag beads via a disulfide bond rather than the previously used 
glutraraldehyde method. To do this, 1 mg/ml ova was prepared in PBS with 2 mM 
EDTA (Thermo Scientific). In a separate tube, 2 mg/ml of Traut’s reagent 
(Thermo Scientific) was prepared in PBS-EDTA. 10 µl of Traut’s solution were 
added to 1 ml of ova, and the solution was rotated for 1 hour at room 
temperature to convert some of the ova amine groups to sulfydryls. After 
incubation, the ova solution was mixed with SPDP-modified biomag beads, 
rotated overnight and extensively washed. 
 
ii. Latex-ova beads 
Latex-ova beads are polystyrene beads covalently conjugated to 
ovalbumin. 
1 µm polystyrene latex (amine group modified) beads were purchased 
from Bangs Laboratories. Beads were washed with PBS and incubated with 10% 
glutaraldehyde (Thermo Scientific) for 2 hours. Beads were washed twice with 
PBS and incubated with 5 mg/ml of ovalbumin in PBS overnight. Beads were 
then washed and resuspended in PBS. 
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iii. Antigen-expressing Bacteria 
*This protocol was designed and performed by Jeff Colbert, UMASS Medical 
School. 
E.Coli (BL21 strain) expressing GST-peptide fusion proteins (GST-
ASNENMETM or GST-SIINFEKL cloned into vector pGEX-6P) were cultured in 
LB+ampilicillin medium overnight. OD600 was adjusted to 0.1 in new LB medium 
containing 0.5mM IPTG. Cultures were then grown from 4-6 hrs at 30oC to an 
OD600 of 1.0. Bacteria were washed 3x by centrifugation in PBS and 
resuspended in 1ml PBS following the last wash. E.coli expressing GST-fusion 
proteins were heat inactivated by incubating cells at 70oC for 50 min vortexing 
bacteria every 15 min. Inactivation of bacteria was confirmed by plating cells on 
LB-agar plates overnight.  Heat inactivated bacteria was resuspended in PBS at 
1X108 cfu/ml. Bacterial cell numbers were determined on live bacteria by 
counting colonies of serially diluted bacteria grown overnight on LB agar plates 
with amplicillin. Colony numbers were calculated from the OD600 of the original 
stock culture. E.coli expressing GST-fusion proteins grown to an OD600 of 1.0 
were shown to correlate to 12.5X106 bacteria/ml. Heat inactivated bacteria were 
cultured with DCs and peptide-specific T cell hybridoma overnight at 37oC. T cell 
activation was determined based the luciferase reporter assay as described.  
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G. Assaying the Classical Pathway with NSova and UbS8L 
In a 384 well plate, 30 µl of DC3.2 NSova and DC3.2 UbS8L cells were 
plated at the indicated cell numbers in media with the indicated amount of 
doxycline. After a period of time (depending on the experiment), 20 µl of reporter 
T cells (corresponding to 1:1 ratio with DCs) were added along with a final 
concentration of 1:1000 brefeldin A (Golgiplug, BD). Brefeldin A stops further 
egress of H2-Kb – SIINFEKL to the surface, thereby allowing titration of peptide-
MHC expression. The cells were incubated overnight and luciferase expression 
of the T cells was measured.   
 
H. Creation of Rab39a CRISPR knockout cells (DC3.2-Rab39aKO) 
Rab39a was knocked out at the genomic level using CRISPR. The target 
sequence was elucidated using an algorithm as presented (112). The guide 
sequence of gtgatcggagactccacggt was chosen because it had an endogenous 
restriction site (BtgI) within the CRISPR cutting site. This allowed screening of 
clones via restriction enzyme digestion. Guide sequence was inserted into 
CRISPR plasmid pX330-U6-Chimeric_BB-CBh-hSpCas9 (Addgene plasmid 
#42230) (113). A gfp construct was PCR amplified from pEGFP-N1 (Clontech) 
and inserted within the Nar1 site of the CRISPR plasmid. 
2x106 DC3.2 were electroporated with 2 µg of the CRISPR construct using 
Amaxa nucleofector II with program T-030 and Cell Line Nucleofector Kit V. Cells 
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were allowed to recover overnight in HCM. GFP expressing cells were flow 
sorted into 96-well plates at 1 cell per well (UMASS Medical School Flow 
Cytometry Core Facility).  
The sorted DC clones were screened by DNA sequencing. DNA from 
clones were extracted using DNeasy Blood and Tissue Kit (Qiagen). A region of 
Rab39a containing the CRISPR target site was PCR amplified using primers    
5’AGGTGCTGAAGGGACAGTTC3’ and 5’AAACTGCGGAGGAGGAAGTC3’. 
PCR products were screened by cutting with BtgI (New England Biolabs). 
Successful mutations generated by CRISPR would have destroyed this cutting 
site. PCR clones that resisted digestion were cloned into PCR2.1-TOPO 
(Invitrogen) according to manufacturer instructions. For every dendritic cell clone, 
10 bacterial clones were sequenced to check mutations in the CRISPR target 
site. Clones that showed exactly 2 different mutations (which indicated that both 
alleles of the gene were mutated) were chosen. 
The generated cell was called DC3.2-Rab39aKO.   
 
I. Rab39a rescue on knockout cells (DC3.2-Rab39KO-Rab39a) 
For Rab39a rescue experiments, a Rab39a CRISPR clone of DC3.2 was 
transduced  with a lentiviral vector containing doxycycline inducible Rab39a. The 
cDNA for Rab39a was amplified from C57BL/6 cDNA, with an HA tag added on 
the N-terminus. This construct was inserted within the Age1 – Mlu1 sites of the 
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plasmid pTRIPZ (GE Dharmacon). Lentivirus production and DC transduction 
was performed as described. Selection was done at 5 µg/ml puromycin. 
Knockout cells were rescued with Rab39a by adding 1 µg/ml doxycycline (Sigma 
Aldrich).  
Western blot was performed to determine expression levels and 
inducibility of the transduced Rab39a (HA-tag). 
The generated cell was called DC3.2-Rab39aKO-Rab39a. 
Some experiments necessitated the need for the Class I molecule H2-Ld. 
H2-Ld was PCR cloned and inserted into the lentiviral vector pCDH1-CMV-SV40-
Bsd. DC3.2-Rab39aKO-Rab39a was transduced using this lentiviral construct. 
These cells were called DC3.2-Rab39aKO-Rab39a-Ld 
To generate GDP (DN) and GTP-locked (CA) Rab39a mutants, mutations 
were generated via pcr using primers as described (102). The DN form of 
Rab39a has an S22N mutation while the CA form has Q72L.The mutant 
constructs were cloned into lentivirus vectors and transduced into DC3.2-
Rab39KO cells.  
The generated cells were called DC3.2-Rab39aKO-Rab39a(DN) and DC3.2-
Rab39aKO-Rab39a(CA). 
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J. pH and DQ ova assay 
i. Beads for assaying protein degradation and pH 
DQ-ovalbumin (Thermo Scientific) was conjugated to Compel 6 µm COOH 
modified beads (Bangs Laboratories) using 1-ethyl-3-[3-
dimethylaminopropyl]carbodiimide hydrochloride (EDC) (Thermo Scientific) 
following manufacturer instructions. 1 mg of DQ-ovalbumin was conjugated to 
200 µl stock beads.  
To make pH sensor beads, the pH sensor dye pHrodo (Thermo Scientific) 
was conjugated to 1 µm latex or Compel 6 µm COOH modified beads. For latex 
beads, 500 µg of pHrodo Green STP Ester was mixed with 100 µl of stock beads 
to make a final volume of 500 µl in PBS. The mixture was rotated overnight and 
washed extensively with PBS. For 6 µm COOH beads, Lysine was conjugated to 
200 µl Compel beads using EDC. After extensive washing with PBS, 500 µg of 
pHrodo Green STP Ester was bound following manufacturer instructions.  
ii. Ova degradation and pH assay 
To assay for overall ova degradation, dendritic cells were fed with DQ-ova 
beads at 1 bead per cell for the listed number of hours. Uneaten beads were 
washed off with PBS and the cells were detached with Versene (Thermo 
Scientific). Cells were resuspended in 1% FCS in PBS for flow cytometric 
analysis. 
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To assay for overall phagosomal pH, dendritic cells were fed with pHrodo 
beads at 1 bead per cell for the listed number of hours. Uneaten beads were 
washed off with PBS and the cells were detached with Versene (Thermo 
Scientific). Cells were resuspended in 1% FCS in PBS for flow cytometric 
analysis. In some cases, cells were treated with 25 nM bafilomycin A1 (Sigma-
Aldrich) during the feeding period. 
K. Staining and Confocal microscopy 
i. Fixed cell microscopy  
For fixed cell imaging, cells were grown in coverslips overnight. The next 
day, cells were washed and fixed with 4% PFA for 10 minutes. Cells were 
permeabilized and stained in 0.25% saponin, 1% BSA in PBS and mounted in 
ProLong Antifade (Thermo Scientific). Cells were imaged under a Leica TCS SP5 
confocal microscope. Image analysis and processing were done in ImageJ 
software. 
ii. Live cell microscopy 
For live cell imaging, DC3.2-Rab39aKO cells were transduced with 
lentivirus containing inducible Rab39a (see previous protocol) fused with an N-
terminal mcherry construct. Cells were grown to 70% confluency in 7mm glass 
bottom dishes (MatTek Corporation) with 1 µg/ml doxycycline overnight. The next 
day, cells were fed with 3 µm polystyrene beads (Bangs Laboratories) for 2 
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hours. Cells were imaged live under a Leica TCS SP5 confocal microscope. 
Image analysis and processing were done in ImageJ software. 
L. Phagosome Flow Cytometry (PhagoFACS) 
i. C6-biotin 
To make biotinylated 6 µm magnetic beads, COMPEL COOH (Bangs 
Laboratories) were conjugated to Biotin Hydrazide (Covachem) using EDC 
(Thermo Scientfic). 
ii. C6-ova biotin 
To make biotinylated ova beads, COMPEL COOH beads were conjugated 
with ovalbumin (Sigma Aldrich) using EDC. After extensive washing, beads were 
conjugated to Biotin-NHS (Thermo Scientific) using manufacturer instructions. 
iii. Phagosome Preparation and Flow Cytometry 
(PhagoFACS) 
Dendritic cells were plated with or without 1µg/ml doxycycline for 24 or 48 
hours in tissue culture plates (12 well or 6 well). After 1-2 days, cells were about 
75% confluent. Media was replaced and dendritic cells were fed with the 
appropriate number and type of biotinylated beads depending on the experiment. 
Phagocytosis was done at 37oC in a 10% CO2 incubator at the listed time point. 
Cells were then washed with PBS and detached with room temperature Versene 
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for 5 minutes. Cells were spun down at 180xg using a swinging bucket centrifuge 
and resuspended in 1% FCS in ice cold PBS. 
Uneaten or surface-bound beads were first stained by incubating cells in 
6.4 µg/ml of Streptavidin Pacific Blue or Orange (Thermo Scientific) in 1% FCS-
PBS for 10 mins on ice. Cells were then washed in 1% FCS-PBS. Cells were 
then resuspended in ice cold homogenization buffer (HB) containing 250 mM 
sucrose, 10 mM CaCl2 with 1X HALT EDTA free protease inhibitor (Thermo 
Scientific). Cell disruption was performed in a 0.3 ml dounce homogenizer 
(Kimble Chase) using the tight fitting “B” pestle. The extent of homogenization 
was observed under a microscope and cells were dounced to at least 50% lysis 
while minimizing disruption of the nucleus. Phagosomes were extracted 
magnetically. 
To stain ruptured phagosomes, phagosomes were washed in Wash Buffer 
(1% BSA in PBS) and stained once again with streptavidin pacific blue/orange for 
10 minutes. After extensive washing, phagosomes were fixed in 2% 
paraformaldehyde for 20 minutes or directly permeabilized and stained. 
For staining, the isolated magnetic bead phagosomes were incubated for 
10 minutes in Perm Buffer (1% BSA in PBS with 0.25% saponin). Phagosomes 
were stained with the indicated antibodies. For FACS analysis, phagosomes 
were resuspended in wash buffer. 
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For flow cytometric analysis of phagosomes, events were gated according 
to the FSC and SSC of plain magnetic beads as well as the lack of Pacific 
Blue/Orange staining. 
iv. Peptide loading of phagosomes 
Isolated, unfixed phagosomes were permeabilized in ice cold Perm Buffer 
supplemented with 1X HALT protease inhibitor (Thermo Scientific). Peptide was 
added (nature and concertation was dependent on the experiment) and the 
mixture was rotated at room temperature for 3-4 hours. The phagosomes were 
washed extensively in Perm Buffer before staining for FACS analysis. 
 
III. Results   
A. Lack of Rab39a inhibits crosspresentation 
 Before characterizing the role of Rab39a in XPT, we sought to validate the 
primary screen and siRNA deconvolution phenotype observed for Rab39a. 
To do this, we transfected DC3.2R with either the smartpool (mixtures of 4 
different oligos against the same gene) or individual siRNA sequences targeting 
Rab39a. The transfected cells were then fed with biomag-ova (ova conjugated to 
magnetic iron oxide beads) and exposed to reporter CD8+ T cells (RF33-Luc). 
The use of smartpool and individual oligos was done to determine if the 
phenotype previously observed in the siRNA screen was due to siRNA artifacts 
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or to a specific requirement for Rab39a in XPT. Smartpool siRNA is primarily 
used to mitigate the off-target effects of each individual oligo through dilution (1/4 
of final concentration), while keeping their effects on the intended target intact. 
However, we also tested the effects of the individual oligos, to make sure that the 
majority of the smartpool components were able to produce the phenotype. Both 
the smartpool (Figure 7), and all individual siRNAs (Figure 8) against Rab39a 
decreased XPT. 
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Figure 7. Rab39a sirna reduces crosspresentation of biomag-ova. 
Figure 7. Rab39a sirna reduces crosspresentation of biomag-ova. 
2.5 x10
3
 DC3.2R cells were transfected with 50 nM sirna pools using 
Lipofectamine RNAiMax. After 48 hours, 1 x 10
4
 Rf33-Luc cells were added 
along with the indicated amounts of biomag ova. After overnight incubation (~18 
hours), Luciferase activity of the T cells were read using Oneglo reagent 
(Promega).  Error bars indicate the standard deviation between triplicate wells. 
Data shown represents one experiment of >3. For all wells with antigen, all p-
values (ANOVA) between Rab39a or β2m vs that of I-Ab are <0.05.  
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Figure 8. The effects of individual Rab39a sirna on crosspresentation. 
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Figure 8. The effects of individual Rab39a sirna on crosspresentation. 
2.5 x10
3
 DC3.2R cells were transfected with 50 nM sirna pools or individual 
oligos using Lipofectamine RNAiMax. After 48 hours, 1 x 10
4
 RF33-Luc cells 
were added along with biomag beads (4 µg of ova). After overnight incubation 
(~18 hours), Luciferase activity of the T cells was read using Oneglo reagent 
(Promega).  *Rab39a-01 to 04 are the individual oligos that comprise the 
smartpool. Error bars indicate the standard deviation between triplicate wells. 
Data shown represents one experiment of >3. Using I-Ab as negative control, 
all siRNA treatments are p<0.05 using ANOVA. 
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  Similar to magnetic bead particles, Rab39a knockdown also inhibited XPT 
from OVA-latex beads, another form of antigen substrate that utilizes the P2C2E 
and P2C2P pathways (Figure 9). Though inherently less efficient than XPT of 
particulate antigen, the cell lines we used were also capable of presenting 
soluble ova, though only at very high protein concentrations. Nevertheless, 
Rab39a was still required for efficient XPT of this form of antigen (Figure 10). 
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Figure 9. Rab39a affects crosspresentation of latex ova. 
Figure 9. Rab39a affects crosspresentation of latex ova. 
2.5 x10
3
 DC3.2R cells were transfected with 50 nM sirna pools using 
Lipofectamine RNAiMax. After 48 hours, 1 x 10
4
 Rf33-Luc cells were added 
along with the indicated amounts of latex ova. After overnight incubation (~18 
hours), Luciferase activity of the T cells were read using Oneglo reagent 
(Promega). Error bars indicate the standard deviation between triplicate wells. 
Data shown represents one experiment of > 3. For all wells with > 5 µg/ml 
antigen, all p-values (ANOVA) between Rab39a or β2m vs that of I-Ab are 
<0.05. 
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Figure 10. Rab39a sirna affects crosspresentation of soluble ova.  
Figure 10. Rab39a sirna affects crosspresentation of soluble ova. 
2.5 x10
3
 DC3.2R cells were transfected with 50 nM sirna using Lipofectamine 
RNAiMax. After 48 hours, 1 x 10
4
 Rf33-Luc cells were added along with the 
indicated concentrations of ova. After overnight incubation (~18 hours), 
Luciferase activity of the T cells were read using Oneglo reagent (Promega). 
For all wells with > 1.25 mg/ml antigen, all p-values (ANOVA) between Rab39a 
or β2m vs that of I-Ab are <0.05.  
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We also confirmed the necessity of Rab39a for XPT by generating a 
conditional Rab39a knockout dendritic cell. Rab39a was knocked out at the 
genetic level using CRISPR. This was done to further confirm that the phenotype 
observed in the siRNA experiments was not due to siRNA off-target effects. The 
generated cell line showed that both alleles of the Rab39a gene were mutated, 
thereby causing frameshifts that prevented the proper expression of full length 
Rab39a (Figure 11). To this knockout cell, we transduced in an HA-tagged 
doxycycline inducible Rab39a construct. Thus, we were able to “rescue” 
expression of Rab39a in knockout cells through the addition of doxycycline 
(Figure 12). XPT of biomag-ova was enhanced upon rescue with Rab39a, 
confirming our previous siRNA knockdown experiments (Figure 13). Interestingly, 
the knockout cells were still capable of XPT, which suggested that either Rab39a 
was not absolutely essential for XPT of this form of antigen or there were 
compensation mechanisms that occurred in long term Rab39a knockouts (as 
opposed to short term knockdowns with siRNA). 
Through two different assays – that of siRNA knockdown and a full 
knockout with CRISPR, we were able to show that efficiency of XPT was 
enhanced by the presence of Rab39a, and this phenotype was not due to artifact 
that might arise from siRNA experiments. 
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Figure 11. DNA sequence of DC3.2 Rab39a CRISPR cells. 
Figure 11. DNA sequence of DC3.2 Rab39a CRISPR cells. 
Rab39a was knocked out using CRISPR and a DC clone was isolated (DC3.2-
Rab39aKO). A region of DNA corresponding to the CRISPR target site for 
Rab39a was amplified through PCR, cloned into TOPO vector and transformed 
into E.coli. Several bacterial clones were sequenced and compared to wt 
Rab39a. The figure shows two different mutations (1 base and 2 base deletion) 
corresponding to both alleles of the Rab39a gene. Alignment done with Multalin 
(http://multalin.toulouse.inra.fr/multalin/) 
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Figure 12. HA-tagged Rab39a is used to rescue Rab39a CRISPR DCs. 
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Figure 12. HA-tagged Rab39a is used to rescue Rab39a CRISPR DCs. 
A doxycycline inducible construct of Rab39a (N-terminal HA-tagged) was 
lentivirally transduced into the generated Rab39a knockout DC (DC3.2-
Rab39aKO) to generate rescuable cells (DC3.2-Rab39aKO-Rab39a). After 
puromycin selection, 5x10
5
 cells were plated in 6 well plates with the indicated 
amount of doxycycline at the indicated amounts of time. Cells were harvested 
and lysed with RIPA buffer then run in a Western Blot. Data shown represents 
one experiment of 2. 
time 
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Figure 13. Rab39a rescue of knockout DCs increases crosspresentation. 
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Figure 13. Rab39a rescue of knockout DCs increases crosspresentation. 
1.25x10
4
 DC3.2-Rab39aKO-Rab39a cells were incubated with 1 µg/ml dox for 
48 hours in a 96 well plate. Then, the indicated amounts of biomag-ova beads 
were added along with 5 x 10
4
 Rf33-Luc. After overnight incubation, luciferase 
activity from the T cells were quantified using Oneglo reagent (Promega). Error 
bars indicate the standard deviation between triplicate wells. Data shown 
represents one experiment of > 3. P-values (ANOVA) at 2 µg ova and beyond 
are < 0.05. 
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B. Silencing Rab39a does not inhibit Class II presentation 
 Next, we sought to confirm the selectivity of Rab39a for XPT by assaying 
for its effect on Class II presentation. The siRNA experiment was performed as 
discussed above but this time, the DCs were exposed to reporter CD4+ T cells 
(MF2-Luc). 
Treatment of cells with Rab39a smartpool siRNA did not inhibit the Class 
II pathway when using biomag-ova (Figure 14), latex -ova (Figure 15) or soluble 
ova (Figure 16). In some cases, a slight increase in Class II presentation was 
observed (data not shown). Rab39a knockdown did not affect Class II 
presentation across the entire antigen dose range. This showed that the lack of 
inhibition of Class II presentation was not due to antigen saturation.  
For the individual oligos, 2 out of 4 caused a decrease in Class II 
presentation (Figure 17). It is in this case that the smartpool data proved 
important. Because dilution of the individual oligos to a 4th of their original 
concentration (in a smartpool) abolished their Class II effect, the observed 
phenotype was probably due to off-target effects of these particular oligos.  
This off-target effect on the Class II pathway was confirmed using Rab39a 
knockout cells. When these knockout cells were rescued through doxycycline 
induction of Rab39a, there was little to no effect on Class II presentation (Figure 
18).  
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Figure 14. Rab39a sirna does not reduce Class II presentation of biomag-ova. 
Figure 14. Rab39a sirna does not reduce Class II presentation of biomag-
ova. 
2.5 x10
3
 DC3.2R cells were transfected with 50 nM sirna pools using 
Lipofectamine RNAiMax. After 48 hours, 1 x 10
4
 MF2-Luc cells were added 
along with the indicated amounts of biomag ova. After overnight incubation (~18 
hours), Luciferase activity of the T cells were read using Oneglo reagent 
(Promega). Error bars indicate the standard deviation between triplicate wells. 
Data shown represents one experiment of > 3. For all wells with antigen, all p-
values (ANOVA) between Rab39a vs that of β2m are > 0.05. For I-Ab vs β2m, 
all are p < 0.05 for wells with antigen. 
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Figure 15. Rab39a does not affect Class II presentation of latex ova. 
Figure 15. Rab39a does not affect Class II presentation of latex ova. 
2.5 x10
3
 DC3.2R cells were transfected with 50 nM sirna pools using 
Lipofectamine RNAiMax. After 48 hours, 1 x 10
4
 Mf2-Luc cells were added along 
with the indicated amounts of latex ova. After overnight incubation (~18 hours), 
Luciferase activity of the T cells were read using Oneglo reagent (Promega). 
Error bars indicate the standard deviation between triplicate wells. Data shown 
represents one experiment of > 3. For all wells with antigen, all p-values 
(ANOVA) between Rab39a vs that of β2m are > 0.05. For I-Ab vs β2m, all are 
p < 0.05 for wells with antigen.  
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Figure 16. Rab39a sirna does not affect  Class II presentation of soluble ova. 
Figure 16. Rab39a sirna does not affect  Class II presentation of soluble 
ova. 
2.5 x10
3
 DC3.2R cells were transfected with 50 nM sirna using Lipofectamine 
RNAiMax. After 48 hours, 1 x 10
4
 MF2-Luc cells were added along with the 
indicated concentrations of ova. After overnight incubation (~18 hours), 
Luciferase activity of the T cells were read using Oneglo reagent (Promega). 
Error bars indicate the standard deviation between triplicate wells. Data shown 
represents one experiment of > 3. For all wells with antigen, all p-values 
(ANOVA) between Rab39a vs that of β2m are > 0.05. For I-Ab vs β2m, all are 
p < 0.05 for wells with antigen. 
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Figure 17. The effects of individual Rab39a sirna on Class II presentation. 
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Figure 17. The effects of individual rab39a sirna on Class II presentation. 
2.5 x10
3
 DC3.2R cells were transfected with 50 nM sirna pools or individual 
oligos using Lipofectamine RNAiMax. After 48 hours, 1 x 10
4
 Mf2-Luc cells were 
added along with biomag beads (0.4 µg of ova). After overnight incubation (~18 
hours), Luciferase activity of the T cells was read using Oneglo reagent 
(Promega).  *Rab39a-01 to 04 are the individual oligos that comprise the 
smartpool. Error bars indicate the standard deviation between triplicate wells. 
Data shown represents one experiment of > 3. Using β2m as negative control, 
p-values (ANOVA) of smartpool, -01 and -04 oligos are not significant. P values 
for -02 and -03 < 0.05. 
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Figure 18. Rab39a rescue of knockout DCs does not affect Class II presentation. 
Figure 18. Rab39a rescue of knockout DCs does not affect Class II 
presentation. 
1.25x10
4
 DC3.2-Rab39aKO-Rab39a cells were incubated with 1 µg/ml dox for 
48 hours in a 96 well plate. Then, the indicated amounts of biomag-ova beads 
were added along with 5 x 10
4
 MF2-Luc. After overnight incubation, luciferase 
activity from the T cells were quantified using Oneglo reagent (Promega). Error 
bars indicate the standard deviation between triplicate wells. Data shown 
represents one experiment of > 3. P-values for all wells between samples are 
not significant based on ANOVA (p>0.05) 
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C. Rab39a knockdown does not affect overall phagosomal pH in 
dendritic cells 
The observation that Rab39a caused a defect in XPT but not Class II 
showed that the gene was playing a selective role in the XPT pathway. If Rab39a 
was necessary for normal cell homeostasis, then its loss would have affected the 
Class II pathway as well (due to cell death or other defects). The lack of effect on 
the Class II pathway also meant that Rab39a was probably not playing a role in 
the common steps between XPT and Class II presentation. These steps include 
antigen acquisition and internalization. This was an interesting finding as Rab39 
was first described as promoting endocytosis when expressed in HeLa cells 
(103).  
Another common step between XPT and the Class II pathway is 
endosome/phagosome maturation. These steps include a decrease in 
phagosomal pH as well as the acquisition and activation of various phagosomal 
proteases. Previously, Rab39a was described to promote phagosome 
acidification (102). In that study, overexpression of the dominant negative form of 
Rab39a (a non functional competitor to the endogenous form’s binding partners) 
decreased the number of phagosomes that colocalized with lysotracker dye (a 
dye that stains acidic compartments). We however, hypothesized that the effect 
of Rab39a on XPT was not due to a change in phagosomal acidification, at least 
in dendritic cells. This was because the MHC Class II pathway relied on 
acidification and subsequent activation of various phagosomal proteases to 
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generate Class II peptides (74, 76). Furthermore, it has been shown that the 
deliberate blocking of endosomal acidification using agents such as chloroquine 
and bafilomycin inhibited Class II presentation (114) (also our unpublished data). 
Thus, if Rab39a promoted phagosomal acidification, then its knockdown would 
have also decreased presentation via the Class II pathway. 
On the other hand, some extent of phagosomal acidification could 
conceivably influence XPT. It could influence vacuolar proteolysis to generate 
MHC I peptides, particularly for the XPT of vacuolar pathway antigens. It could 
destabilize MHC I molecules and in theory possibly promote exchange of MHC I- 
bound peptides with ones derived from internalized antigen. 
In order to directly determine the role of Rab39a on phagosomal 
acidification, we fed dendritic cells with pH sensing beads. Beads conjugated to a 
pH sensor dye (pHrodo, Thermo Scientific) were fed to siRNA treated dendritic 
cells. This dye increased fluorescence as the environment pH became more 
acidic. If Rab39a was necessary for acidification, then its knockdown should 
have caused a decrease in bead fluorescence. As shown in (Figure 19), we did 
not see significant changes in fluorescence by cells that were treated with 
Rab39a siRNA as compared to cells treated with control siRNA. In contrast, the 
vacuolar ATPase inhibitor Bafilomycin A1 effectively prevented phagosomes 
from acidifying as expected, and served as a positive control that the assay was 
working.  
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The same lack of phenotype was observed when pH sensing beads were 
fed to either Rab39a knockout cells or doxycycline induced / rescued cells 
(Figure 20). Thus, it appears that for the cell lines we are using, phagosome 
acidification proceeded normally despite the lack of Rab39a. 
The discrepancy between our results and that of previously published data 
(102) can be attributed to several factors. First, we utilized dendritic cell lines 
while the previous study used macrophages. It has been shown that dendritic 
cells, unlike macrophages, have specialized pathways to neutralize phagosomal 
pH (73). Second, the method of Rab39a disruption was different between our 
and the published experiments. In our experiments, we reduced Rab39a via 
siRNA, or eliminated it completely via CRISPR. In the published work, Rab39a 
was disrupted through the overexpression of the dominant negative form (GDP 
locked form) of Rab39a. While the dominant negative forms of Rab GTPases are 
usually used to compete out the wildtype forms from their natural binding 
partners, there are some cases where the GDP bound form of a Rab protein has 
a unique function as compared to its GTP bound form (discussed further in later 
sections) (69, 115-117). In addition, dominant negative forms of proteins have 
the potential to block other interacting proteins and thereby cause broader 
inhibitory effects that selective depletion of the wild type protein. 
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Figure 19. Rab39a does not affect overall phagosome pH. 
I-Ab 
β2m 
Rab39a 
100nM bafilomycin 
cells alone 
Figure 19. Rab39a does not affect overall phagosome pH. 
8 x 10
4
 DC3.2R cells were transfected with 50 nM sirna using lipofectamine 
RNAiMax in a 24 well plate. 48 hours later, cells were fed at 10 beads / cell of 1 
µm pHrodo latex beads for 2 hours at 37
o
C. Wells were washed and the cells 
were detached with trypsin, washed in 1%FCS-PBS then run for facs analysis. 
For control, untransfected cells were treated with 100 nM bafilomycin during 
phagocytosis. Shown are gMFI of indicated fluors. Data shown represents one 
experiment of >3. 
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Figure 20. Rab39a rescue does not affect overall phagosome pH. 
No dox 
Dox 
Cells alone 
Figure 20. Rab39a rescue does not affect overall phagosome pH. 
1.25 x 10
5
 DC3.2-Rab39aKO-Rab39a cells were incubated with 1 µg/ml dox for 
48 hours in a 12 well plate. Cells were fed at 1 bead / cell of 6 µm magnetic 
beads  conjugated with pHrodo for 4 hours at 37
o
C. Wells were washed and the 
cells were detached with versene, washed in 1%FCS-PBS then run for facs 
analysis. Shown are gMFI of cells that have eaten beads. Data shown 
represents one experiment of >3. 
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D.  GDP and GTP locked Rab39a as well as Rab39b do not 
affect XPT 
To further characterize role of Rab39a in the XPT pathway as well as 
address the previously discussed discrepancy in data, we utilized the dominant 
negative (DN, GDP-locked) and constitutively active (CA,GTP-locked) forms of 
Rab39a in our CRISPR rescue experiments. 
Rab proteins, being GTPases, can either be in a guanosine diphosphate 
(GDP)-bound or guanosine triphosphate (GTP)-bound form (118). The activation 
state of the Rab determines its function, with many Rabs only being active when 
gtp is bound. Because of this, several studies on Rab GTPases have made use 
of Rab mutants, wherein the GTPase is permanently bound to GDP or GTP. 
Dominant negative mutants can be overexpressed to compete out endogenous 
Rabs from their interaction partners, thereby inhibiting their function. The reverse 
is true for constitutively active mutants, which when overexpressed, have no 
need for prior activation.  
To test the effect of the Rab39a DN and CA forms in XPT, we transduced 
the Rab39a knockout cells with doxycycline inducible forms of these Rab39a 
mutants. Interestingly, only the wildtype form of Rab39a, and not DN or CA, 
could enhance crosspresentation of bead bound antigen (Figure 21). While this 
was expected for the DN, the lack of phenotype even with the CA form was 
102 
 
surprising. These data suggest that the proper cycling of Rab39a from the GDP 
to the GTP bound form (and back) was important for conveying the XPT 
phenotype.  
It is important to note that the wt, DN and CA rescue cell lines used in this 
experiment arose from separate transductions of lentivirus constructs. The 
random integration of the constructs in the genome, as well as the time needed 
for proper antibiotic selection of transduced clones caused these three cell lines 
(wt, DN and CA) to diverge in their characteristics. These characteristics included 
cell size, division time, culture plate adherence properties, Class I and 2 levels, 
as well as crosspresentation and Class 2 presentation abilities. As such, in figure 
21, one cannot compare the reporter T cell signals (RLU) of the three cell lines 
against each other (eg. Wt vs DN baseline xpt). What this figure shows, is the 
effect of dox (Rab39a rescue) on each of the independent cell lines.    
 The requirement for a fully functional Rab GTPase on-off cycle was also 
described with Rab3a (116). In mouse chromaffin cells, only the wt form of 
Rab3a was able to regulate secretory vesicle docking, while both DN and CA 
forms failed to do so. In a large scale screen for Drosophila Rab effectors, it was 
shown that while majority of effector proteins bound to the GTP-bound form of 
Rab GTPases, there are indeed some that prefer the GDP bound form (117). 
Rab22a, involved in recycling of cell surface molecules including MHC Class-I, 
has also been shown to require both GDP and GTP bound forms for full activity 
(69). Knockdown of Rab22a or overexpression of its DN form blocked MHC-I 
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recycling and depleted recycling tubules in human cell lines. When the CA form 
was overexpressed however, there was an increase in recycling tubules and 
peripheral vesicles, but MHC-I recycling was still defective. The data suggested 
that while the active form of Rab22a was required to initiate the formation of 
recycling tubules and vesicles, its inactivation is required for fusion of these 
vesicles to the cell surface. Our data show that Rab39a is similar in that it 
requires active GDP/GTP cycling to confer its phenotype on XPT. 
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Figure 21. Mutants of Rab39a cannot rescue of crosspresentation of knockout DCs. 
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Figure 21. Mutants of Rab39a cannot rescue of crosspresentation of 
knockout DCs. 
DC3.2-Rab39aKO cells were transduced with doxycycline inducible constructs 
containing the wt sequence of Rab39a, or its DN (S22N), or CA (Q72L) mutants 
and selected with puromycin. 1.25x10
4
 cells were incubated with 1 µg/ml dox 
for 48 hours in a 96 well plate. Then, the indicated amounts of biomag-ova 
beads were added along with 5 x 10
4
 Rf33-Luc. After overnight incubation, 
luciferase activity from the T cells were quantified using Oneglo reagent 
(Promega). Error bars indicate the standard deviation between triplicate wells. 
Data shown represents one experiment of > 3. For Rab39a (wt), all wells with 
antigen at and beyond 2 µg ova have p-values (ANOVA) < 0.05. P-values for all 
wells in both DN and CA setups are n t significant (p > 0.05) 
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Further investigation of the Rab39a mutants showed that while both 
Rab39a wt and CA forms were stable in the cell, the DN form had a short half 
life. As shown in (Figure 22), cells expressing the DN form had very low levels of 
Rab39a unless rescued by addition of the proteasome inhibitor MG132. This 
might indicate a difference in Rab39a regulation between dendritic cells (our 
data) and macrophages (102), where overexpression of the DN form decreased 
phagosome acidification. Why the stable CA form did not cause an increase in 
XPT would be interesting to study.  
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Figure 22. Mutants of Rab39a have differing protein stabilities. 
HA-tag 
(overexposed) 
HA-tag 
CA 
Figure 22. Mutants of Rab39a have differing protein stabilities. 
DC3.2-Rab39aKO cells were transduced with Doxycycline inducible constructs 
containing the wt sequence of Rab39a, or its DN (S22N), or CA (Q72L) mutants 
and selected with puromycin. 1 x 10
6
 cells were incubated with or without 1 
µg/ml dox for 24 hours in a 6 well plate. A set of cells preincubated with dox 
were further incubated with 10 µM MG132 for 4 hours. Cells were harvested, 
lysed in RIPA buffer and run in a Western Blot. Data shown represents one 
experiment of >3. 
β-actin 
Dox 
MG132 
- + + - + + - + + 
- + - - + - - + - 
DN wt 
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Rab39b is another isoform (different gene with high homology of protein 
sequence) of Rab39 that shares 78% amino acid similarity with Rab39a (104). 
This difference in amino acid sequence completely changed Rab39a and b 
localization. While Rab39a was present on late endosomes, Rab39b was golgi-
localized (105). Nevertheless, we tested whether Rab39b also affected XPT.  
Silencing of Rab39b with siRNA did not affect XPT of biomag-ova (Figure 
23). Thus, despite high sequence homology, Rab39a was distinct enough from 
Rab39b to affect XPT. We hypothesized that the endosomal localization of 
Rab39a was the reason and this is discussed in the later sections. 
108 
 
Figure 23. Rab39b does not affect crosspresentation.  
0 5 1 0 2 0 4 0
0
2 0 0 0
4 0 0 0
6 0 0 0
8 0 0 0
1 0 0 0 0
x p t o f  b io m a g -o v a
g /m l ova
R
L
U
I -A b
 2m
R a b 3 9a
R a b 3 9b
Figure 23. Rab39b does not affect crosspresentation. 
A. 2.5 x10
3
 DC3.2R cells were transfected with 50 nM sirna pools using 
Lipofectamine RNAiMax. After 48 hours, 1 x 10
4
 Rf33-Luc cells were added 
along with the indicated amounts of biomag ova. After overnight incubation (~18 
hours), Luciferase activity of the T cells were read using Oneglo reagent 
(Promega). Error bars indicate the standard deviation between triplicate wells. 
For all wells, p-values (ANOVA) between Rab39b vs that of β2m are not 
significant (> 0.05). B. qPCR of Rab39a and Rab39b following siRNA 
treatments. Expression was normalized to that of siRNA control (I-Ab). Data 
shown represents one experiment of > 3. 
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E. Silencing Rab39a does not inhibit the Classical Pathway  
Given that inhibition or lack of Rab39a affected XPT but not the Class II 
pathway, we next determined whether or not Rab39a affected the Classical MHC 
Class I pathway. The XPT and Classical pathways are intricately linked by 
several key molecules. 
The phagosome to cytosol pathways (P2C2E and P2C2P) of XPT shared 
with the Classical pathway genes such as TAP1, the proteasome, and in some 
cases, other peptidases like ERAP1 (28, 29, 31, 32) (33). Moreover, for XPT 
antigens that route through the ER for Class I loading, pathways that allow MHC-
I egress and trafficking to the cell surface are also shared. 
A XPT antigen that routed through the vacuolar pathway could also be 
potentially affected by components of the Classical pathway. The source of 
MHC-I utilized for phagosomal loading has been proposed to come from the cell 
surface, the endpoint of the Classical pathway (65-69). Class I stability and 
peptide loading in the ER could also be important, as several models proposed 
that MHC-I loaded with low affinity peptides in the ER were the ones primarily 
being loaded with peptides derived from phagosomally processed antigens (119, 
120). Thus, genes that encoded proteins that altered the MHC peptide repertoire 
(chaperones, peptidases, etc) could be important for both pathways. 
In order to determine the role of Rab39a in the Classical Class I pathway, 
we transfected siRNA into two different ova expressing cell lines. 
110 
 
First, we generated a dendritic cell line that could inducibly express a 
cytosolic form of ovalbumin (DC3.2 NS-ova) upon addition of doxycycline. The 
expressed ovalbumin protein underwent all the steps involved in the Classical 
pathway – proteasomal processing, import into the ER through TAP1, trimming 
by ERAP and finally Class I loading in the ER and egress toward the surface.  
We also generated a second DC line (DC3.2 Ub-S8L) that instead 
inducibly expressed the SIINFEKL peptide conjugated to the C-terminus of 
Ubiquitin (110). In this cell, deubiquitinases free the S8L peptide, thereby 
bypassing proteasomal processing and peptidase trimming (121). The S8L 
peptide however, still required transport through TAP1 and ER loading onto 
Class I.  
We utilized both cell lines to be able to distinguish between the antigen 
processing and Class I-loading steps of the Classical pathway. A defect in NSova 
presentation but not UbS8L would probably mean a defect in a cytosolic (or ER) 
antigen processing step (protein unfolding, chaperoning to proteasome, trimming, 
etc). A defect in both NSova and UbS8L would likely point to a defect in peptide 
transport (through TAP1) or MHC-I trafficking (from the ER to the cell surface). 
 Knocking down Rab39a in these cell lines showed no defect in Class I 
presentation of S8L (Figure 24). Because the Classical pathway is much more 
efficient that XPT, there was a danger of oversaturating the system with MHC-
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peptide. Titration of doxycycline allowed for the expression of minute amounts of 
antigen, and even in these cases, Rab39a did not have an effect. 
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Figure 24. Rab39a does not affect the Classical Class I pathway. 
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Figure 24. Rab39a does not affect the Classical Class I pathway. 
2.5 x10
3
 DC3.2 NS-ova or DC3.2 UbS8L cells were transfected with 50 nM sirna 
pools using Lipofectamine RNAiMax. After 48 hours, the listed concentrations 
of doxycycline were added. After 6 hours (NS-ova) or 2 hours (UbS8l) incubation 
at 37
o
C, Classical presentation was stopped by the addition of 1:1000 Brefeldin 
A (Golgiplug, BD). 1  x 10
4
 Rf33-Luc cells were added and luciferase activity 
measured after overnight incubation. Error bars indicate standard deviation of 
triplicate wells. Data represents one experiment of > 3. Using I-Ab as negative 
control, for all wells with dox, p-values of β2m are < 0.05 (ANOVA). None of the 
wells for Rab39a show significant difference compared to the control. 
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 We also looked at the effect of Rab39a on surface MHC Class I levels via 
flow cytometric analysis of siRNA treated cells. This allowed determination of 
overall peptide supply because peptide-binding is required for MHC I molecules 
to exit the ER and therefore reduction in peptide supply reduces steady state 
surface Class I levels. Defects in MHC-I trafficking could also be observed using 
this assay. The steady state levels of MHC Class I were unchanged despite 
Rab39a knockdown (Figure 25). The same phenotype was observed when we 
rescued knockout cells with Rab39a (Figure 26). 
These data indicated that Rab39a affected XPT in a process distinct from 
those shared with the Classical pathway. Because of this, and Rab39a’s 
published endosomal localization (102, 105), we then focused on the 
phagosomal processes that occur during XPT.  
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Figure 25. Rab39a sirna does not affect surface MHC Class I levels. 
Figure 25. Rab39a sirna does not affect surface MHC Class I levels. 
8 x 10
4
 DC3.2R cells were transfected with 50 nM sirna using lipofectamine 
RNAiMax in a 24 well plate. 48 hours later, cells were detached and stained for 
MHC Class I (H2-K
b
). Shown are gMFI of indicated stains 
I-Ab 
β2m 
Rab39a 
Unstained 
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Figure 26. Rab39a rescue does not change steady state surface MHC Class I levels. 
Figure 26. Rab39a rescue does not change steady state surface MHC 
Class I levels. 
1.25 x 10
5
 DC3.2-Rab39aKO-Rab39a-L
d
 cells were incubated with or without 1 
µg/ml dox for 48 hours at 37
o
C in a 12 well plate. Cells were trypsinized, washed 
and stained for surface Class I (H2-K
b
 and H2-D
b
). Shown are gMFIs of the 
indicated stains 
No dox (KO) 
Dox (rescue) 
unstained 
No dox (KO) 
Dox (rescue) 
unstained 
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F. Rab39a is localized to late endosomes as well as antigen 
containing phagosomes 
Before studying the possible roles of Rab39a in the phagosomal steps of 
XPT, we sought to reconfirm the findings that it was indeed endosomally 
localized and was recruited to antigen containing phagosomes (102). 
In order to do this, we rescued our generated knockout cells with 
doxycycline (DC3.2 Rab39aKO-Rab39a) and stained Rab39a (via an HA tag) as 
well as endosomal markers for confocal microscopy. Confirming the previous 
reports, Rab39a colocalized with both Rab7 (Figure 27) and Lamp2 (Figure 28), 
both markers of late endosomes. 
We also rescued the knockout cells with an mcherry tagged Rab39a. This 
allowed for live cell observations during microscopy. Rab39a assumed a 
punctate pattern. When cells were fed overnight with lysosensor dextran (which 
fluoresces at 521 nm when in acidic conditions), Rab39a could be seen 
surrounding the antigen (Figure 29). It has been reported that the terminal 
destination of endocytosed dextrans are Lamp1 positive, Rab7 positive 
compartments (122). Thus, Rab39a localized with late endosomal compartments 
in live cells. 
Mcherry-Rab39a also colocalized with internalized beads in the live cell 
imaging experiments (Figure 30). Thus, Rab39a was recruited not just to 
endosomes, but also to particulate containing phagosomes.  
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Figure 27. Rab39a colocalizes with Rab7. 
Figure 27. Rab39a colocalizes with Rab7. 
DC3.2-Rab39aKO-Rab39a were grown in round coverslips placed in a 12 well plate. After overnight incubation 
with 1 µg/ml doxycycline, cells on coverslips were washed, fixed and stained according to the listed protocol and 
antibodies. A. Green = Rab39a (HA tag), B. Red = Rab7, C. Merge, D. Brightfield. Arrows highlight colocalization. 
A. B. 
C. D. 
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Figure 28. Rab39a colocalizes with Lamp2.
Figure 28. Rab39a colocalizes with Lamp2. 
DC3.2-Rab39aKO-Rab39a were grown in round coverslips placed in a 12 well plate. After overnight incubation 
with 1 µg/ml doxycycline, cells on coverslips were washed, fixed and stained according to the listed protocol and 
antibodies. A. Green = rab39a (HA tag), B. Red = Lamp2, C. Merge, D. Brightfield. Arrows highlight punctate 
structures with colocalization 
A. B. 
C. D. 
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Figure 29. Rab39a colocalizes with acidic vesicles. 
Figure 29. Rab39a colocalizes with acidic vesicles. 
DC3.2-Rab39aKO cells were transduced with a doxycycline inducible construct 
containing mcherry-Rab39a.  Cells were plated in 35 mm glass bottom dishes 
(MatTek) overnight with 1 µg/ml dox. The next day, cells were incubated with 
1mg/ml lysosensor yellow/blue dextran. After overnight incubation at 37
o
C, cells 
were imaged under a Leica TCS SP5 confocal microscope. Green = lysosensor 
emission at 521 nm showing acidic compartments.. Red = mcherry- rab39a. 
Arrows highlight internalized dextran surrounded by Rab39a. 
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Figure 30. Rab39a colocalizes with phagocytosed latex beads. 
Figure 30. Rab39a colocalizes with phagocytosed latex beads. 
DC3.2-Rab39aKO cells were transduced with a doxycycline inducible construct 
containing mcherry-Rab39a.  Cells were plated in 35 mm glass bottom dishes 
(MatTek) overnight with 1 µg/ml dox. The next day, 1 µm latex beads conjugated 
with Alexa 488-NHS (1 bead / cell) were added. After 2 hours at 37
o
C, cells were 
imaged under a Leica TCS SP5 confocal microscope. Green = Alexa 488 
labeled beads. Red = mcherry-rab39a. Arrows highlight internalized beads 
surrounded by Rab39a. 
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G. Flow cytometric analysis of isolated phagosomes 
(PhagoFACS) 
Recent studies have indicated that certain processes involved in XPT 
occur at the individual phagosome level. For instance, MHC Class I from the ER-
golgi intermediate compartment (ERGIC) have been shown to be recruited to 
specific phagosomes containing TLR4 ligands (71). In another case, it has been 
shown that XPT efficiency was enhanced when the antigen and a TLR signal 
was present in the same compartment, as opposed to pretreating cells with TLR 
ligands prior to antigen exposure (123). Because these phagosomal events might 
occur in a minority of the overall phagosomes in the cell, we needed to develop a 
method to be able analyze individual phagosomes at a sensitivity and resolution 
higher than that afforded microscopy.  
Because of this, we performed flow cytometric analysis on isolated 
phagosomes (PhagoFACS), following and further optimizing the protocol as 
presented in a previous work (124). In this protocol, we fed dendritic cells with 
magnetic beads, then isolated these beads after cell disruption. The magnetic 
phagosomes were able to be efficiently separated from the rest of the cell 
components, greatly reducing background signal usually found during 
microscopy. This also allowed us to analyze phagosomes at an individual level, 
and distinguish subclasses of phagosomes present in the cells. The gating 
strategy we employed in this analysis is shown (Figure 31). 
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Figure 31. Gating strategy for phagosomes.
Cell lysate 
Magnetic 
bead 
phagosomes 
Figure 31. Gating strategy for phagosomes. 
1.25 x 10
5
 DC3.2-Rab39aKO-Rab39a-L
d
 cells were incubated with or without 1 µg/ml dox for 48 hours in a 12 well 
plate. Cells were fed at 1 bead / cell of biotinylated 6 µm magnetic beads for 2 hours. Then, the cells were exposed 
to Streptavidin-Pacific blue to stain uneaten beads. Phagosomes were then isolated using the listed protocol and 
broken phagosomes were stained through another round of Streptavidin- Pacific Blue. Isolated phagosomes were 
washed, permeabilized and stained for Lamp-1 (shown on APC channel).   
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H. Rab39a is recruited to late phagosomes but is not necessary 
for phagosome maturation.  
We used PhagoFACS to study phagosomal Rab39a in our generated KO 
vs reconstituted cells (DC3.2-Rab39aKO-Rab39a). As shown in (Figure 32), 
Rab39a was recruited to magnetic bead containing phagosomes. The signal was 
specific as no staining was observed when the cells did not express Rab39a. In 
agreement with previous findings (102, 105) , Rab39a was a late endosomal Rab 
GTPase, as most of the phagosomes were positive for Rab39a only at later time 
points. Rab39a had similar kinetics to Lamp1 and its presence or absence did 
not affect Lamp1 recruitment, in agreement with previous reports (105) (Figure 
33). These data showed that Rab39a was recruited as the phagosome matured, 
and its recruitment to the phagosome membrane was not required for 
phagosome maturation. 
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Figure 32. Rab39a is recruited to magnetic bead phagosomes. 
Beads alone Control cells 
Rab39a CRISPR cells 
-dox 
(KO) 
+dox 
(rescue) 
15 mins 30 mins 60 mins 
60 mins N/A 
Figure 32. Rab39a is recruited to magnetic bead phagosomes. 
5 x 10
5
 DC3.2-Rab39aKO-Rab39a cells were incubated with or without 1 µg/ml 
dox for 24 hours in a 6 well plate. Cells were fed at 1 bead / cell of biotinylated  
6 µm magnetic beads for the indicated lengths of time. Magnetic bead 
phagosomes were isolated using the listed protocol. Phagosomes were 
washed, permeabilized and stained for Rab39a (HA-tag). Data shown 
represents one experiment of >3. 
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Figure 33. Rab39a does not affect Lamp-1 recruitment to phagosomes. 
Rab39a CRISPR cells 
-dox 
(KO) 
+dox 
(rescue) 
15 mins 30 mins 60 mins 
Beads alone Control cells 
60 mins N/A 
Figure 33. Rab39a does not affect Lamp-1 recruitment to phagosomes. 
5 x 10
5
 DC3.2-Rab39aKO-Rab39a cells were incubated with 1 µg/ml dox for 24 
hours in a 6 well plate. Cells were fed at 1 bead / cell of biotinylated  6 µm 
magnetic beads for the indicated lengths of time. Magnetic bead phagosomes 
were isolated using the listed protocol. Phagosomes were washed, 
permeabilized and stained for Lamp-1. Data shown represents one experiment 
of >3. 
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I. Wt and CA Rab39a localizes to the phagosome but the DN 
form does not  
We then looked if the DN and CA mutants of Rab39a were being recruited 
to phagosomes, to see if this explained the lack of phenotype we observed 
during our rescue experiments. Using PhagoFACS, we saw that that while the wt 
and CA forms of Rab39a were recruited to the phagosome, the DN form was not 
(Figure 34). This was perhaps due to the high turnover rate of DN in dendritic 
cells. Nevertheless, a previous study has shown that at least in HeLa cells, the 
DN form acquired a disperse/cytosolic localization as compared to the wt form, 
which mainly localized to late endosomes and vesicular structures (108). The CA 
form did not rescue XPT despite being recruited to the phagosomes (Figure 21). 
Further studies are needed to clarify this observation. 
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Figure 34. WT and CA, but not DN  Rab39a are recruited to magnetic bead containing phagosomes.
Rab39a (WT) Rab39a (DN) Rab39a (CA) 
No dox (KO) 
Dox (rescue) 
beads alone 
Figure 34. WT and CA, but not DN  Rab39a are recruited to magnetic bead containing phagosomes. 
DC3.2-Rab39aKO cells were transduced with doxycycline inducible constructs containing the wt sequence of 
Rab39a, or its DN (S22N), or CA (Q72L) mutants and selected with puromycin. 1.25 x 10
5
 cells were incubated 
with or without 1 µg/ml dox for 48 hours in a 12 well plate. Cells were fed at 1 bead / cell of biotinylated 6 µm 
magnetic beads for 2 hours. Phagosomes were isolated using the listed protocol. Isolated phagosomes were 
washed, permeabilized and stained for Rab39a (HA-tag). Shown are phagosomal gMFI of indicated stains. Data 
shown represents one experiment of >3. 
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J. Silencing Rab39a reduces XPT of vacuolar pathway antigens 
 Because Rab39a was phagosomal and did not affect the Classical 
Pathway of XPT, we then asked if Rab39a would affect the Vacuolar Pathway of 
XPT. The vacuolar pathway did not share the cytosolic steps involved in the 
Classical Pathway such as proteasome processing and TAP transport of 
peptides. Antigens that routed through the vacuolar pathway did not even need 
transport from the phagosome to the cytosol. Assaying the effect of Rab39a on 
this pathway would also shed light if Rab39a was playing a role in this transport 
process. 
Our lab has previously described a vacuolar pathway for XPT of polymer-
based beads and cell associated antigen (27). This pathway was shown to be 
TAP independent, and primarily used phagosomal proteases such as Cathepsin 
S to process antigen, bypassing the proteasome altogether. Other forms of 
antigen, such as bacteria, have been described to follow a similar route (46, 47). 
We therefore used heat-killed E. coli expressing GST fused to either SIINFEKL 
or ASNENMETM as a source of vacuolar pathway / TAP-independent antigen. In 
cells wherein Rab39a was knocked down via siRNA, XPT of these bacterial 
forms of antigen was reduced (Figure 35). 
The observed data further supports our hypothesis that Rab39a was 
affecting XPT in a process that was occurring within the phagosomes. The 
bacterial antigens we used had no need for TAP, suggesting that they had no 
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need for phagosome to cytosol transfer (as TAP is used for ER or phagosome 
entry from the cytosol). Because of this, we also hypothesized that the effect of 
Rab39a on XPT was not just due to a role in phagosome to cytosol transport of 
antigen. 
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Figure 35. Rab39a affects crosspresentation of TAP independent bacterial antigens. 
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Figure 35. Rab39a affects crosspresentation of TAP independent bacterial 
antigens. 
1.25 x10
4
 DC3.2R cells were transfected with 50 nM sirna pools using 
Lipofectamine RNAiMax. After 48 hours, 5 x 10
4
 Rf33-Luc or 12.64-Luc cells 
were added along with the indicated amounts of heat killed bacteria (E.coli). 
After overnight incubation (~18 hours), Luciferase activity of the T cells were 
read using Oneglo reagent (Promega).  (Experiment done by Colbert, J) 
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K. Rab39a inhibits phagosomal degradation of antigens 
In the case of biomag-ova, latex bead-ova and soluble ova, one way 
Rab39a could have affected the XPT of these antigens was through the 
modulation of antigen degradation in the phagosomes. These forms of antigen 
were previously shown to be processed mainly in the cytosol by the proteasome, 
as proteasome inhibitors completely abolished presentation (in this case, ova-
beads) (33). Furthermore, the presentation of these antigens was resistant to 
chloroquine, a weak base that inhibits phagosomal proteases by increasing 
phagosome pH (33). Supporting this, excessive antigen degradation in the 
phagosomes was shown to be detrimental to the XPT of these antigens (73, 
125). Dendritic cells express the NADPH oxidase (NOX2) complex that 
alkalinizes the phagosomes, preventing excessive degradation of antigen (73). 
When this complex was perturbed, crosspresentation of ova was reduced. When 
the transcription factor TFEB was overexpressed in DCs, XPT of ova was 
decreased due to enhanced phagosomal proteolytic activity (125). In APCs, 
TFEB positively regulated phagocytosis and lysosomal functions. Thus, it was 
possible that the lack of Rab39a somehow caused increased degradation of ova 
in our experiments that led to decreased XPT. 
To test this, we fed knockout or Rab39a rescued DCs with beads 
conjugated to DQ-ovalbumin (DQ-ova). DQ-ova is ovalbumin attached to Bodipy 
FL dye. While the ova protein is intact, the high concentration and proximity of 
the attached dyes cause them to self-quench, resulting in low fluorescence. Upon 
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ova degradation, the dyes are freed, resulting in bright fluorescence. When we 
analyzed whole cells (Figure 36), we saw a very slight decrease in ova 
degradation in cells that expressed Rab39a.  
However, when we looked at isolated phagosomes, we saw a much 
bigger phenotype. Knockout or rescued cells were fed with magnetic beads 
conjugated to ovalbumin. After the phagosomes have been isolated, the level of 
ovalbumin remaining on the beads/phagosomes was determined by staining with 
a monoclonal anti-ova antibody. This assay has shown that Rab39a reduced ova 
degradation in the phagosomes (Figure 37).  
Because of this finding, one could hypothesize that Rab39a was 
preventing excessive antigen degradation in the phagosomes, thereby 
preserving more antigen that could feed into the XPT pathway. 
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Figure 36. Rab39a slightly reduces overall ova degradation. 
No dox (KO) 
Dox (rescue) 
Cells alone 
Figure 36. Rab39a slightly reduces overall ova degradation. 
1.25 x 10
5
 DC3.2-Rab39aKO-Rab39a cells were incubated with 1 µg/ml dox for 
24 hours in a 12 well plate. Cells were fed at 1 bead / cell of 6 µm magnetic 
beads  conjugated with DQ ova 4 hours at 37
o
C. Wells were washed and the 
cells were detached with versene, washed in 1%FCS-PBS then run for facs 
analysis. Shown are gMFI of cells that have eaten beads. Data shown 
represents one experiment of >3. 
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Figure 37. Phagosomes from Rab39a positive cells are less degradative.  
No dox 
Dox 
beads alone 
Figure 37. Phagosomes from Rab39a positive cells are less degradative 
A. Representative experiment. 1.25 x 10
5
 DC3.2-rab39aKO-rab39a-L
d
 cells 
were incubated with or without 1 µg/ml dox for 48 hours in a 12 well plate. Cells 
were fed at 1 bead / cell of biotinylated-ova conjugated to 6 µm magnetic beads 
for 4 hours. Isolated phagosomes were washed, permeabilized and stained for 
ovalbumin. B. As in A, but showing combined data for 5 independent 
experiments. The paired student’s t-test is p=0.0025. C. As in B, but the MFI of 
dox setups was normalized to no dox to show extent of inhibition of ova 
degradation. 
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i. Rab39a does not enhance XPT by limiting degradation 
of ovalbumin 
 While we observed that Rab39a was inhibiting phagosomal degradation of 
ova, we wanted to know if this inhibition of degradation was responsible for the 
augmentation of XPT seen in Rab39a expressing cells. This was because we 
also found that Rab39a was necessary for the efficient XPT of vacuolar pathway 
antigens - a process that heavily depended on phagosomal proteases (27). Thus, 
if Rab39a inhibited degradation of antigen to preserve them for the phagosome 
to cytosol pathway (biomag-ova), then its knockdown should have enhanced the 
presentation of vacuolar bacteria-ova. 
To examine this, we deliberately inhibited phagosomal degradation by 
treating knockout or Rab39a rescued dendritic cells with leupeptin - a broad 
inhibitor of cysteine and serine proteases. Once again, Rab39a expressing cells 
were better at XPT as compared to the knockout (Figure 38). Furthermore, the 
advantage of Rab39a rescued cells over the knockout remained in the presence 
of inhibitor.  
Because the deliberate inhibition of phagosomal degradation did not 
abolish the XPT advantage of Rab39a expressing cells, we hypothesized that 
Rab39a improved DC XPT in a mechanism(s) distinct from just the inhibition of 
antigen degradation. 
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Figure 38. Leupeptin does not increase XPT and does not abolish Rab39a phenotype.  
Figure 38. Leupeptin does not increase xpt and does not abolish rab39a 
phenotype. 
1.25x10
4
 DC3.2-Rab39aKO-Rab39a cells were incubated with 1 µg/ml dox for 
48 hours in a 96 well plate. Then, biomag-ova beads (µg of ova)  were added 
along with 5 x 10
4
 Rf33-Luc with or without the listed final concentration of 
leupeptin. After overnight incubation, luciferase activity from the T cells were 
quantified using Oneglo reagent (Promega). Error bars indicate standard 
deviation between triplicate wells. * p<0.05 based on ANOVA. Data represents 
one experiment of 3. 
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L. Rab39a affects peptide loading in the phagosome 
Our experiments have so far suggested that Rab39a was playing a role in 
the phagosomes that was not involved in antigen processing. We then reasoned 
that perhaps Rab39a was facilitating XPT by enhancing peptide loading in the 
phagosomes. This could be achieved through several ways. Rab39a could have 
been delivering MHC Class I molecules to the phagosome for loading. It could 
also have been delivering specialized chaperones that mediate peptide loading 
onto Class I (similar to H2-DM and DO in the Class II pathway). Perhaps it could 
also have been modulating the phagosome environment to optimize Class I 
loading (though we did not observe a significant effect on pH by Rab39a). 
 To test if Rab39a affected peptide loading in the phagosomes, we initially 
made use of N and C terminally extended SIINFEKL beads (peptide beads). We 
extended the SIINFEKL peptide by a cysteine containing amino acid stretch at 
the N or C terminal end, allowing us to conjugate these peptides to magnetic 
beads via a disulfide bond.  
The rationale of this was that these peptides would not need proteases to 
be released from the beads, as opposed to covalently bound full length ova. 
Instead, these peptides would be released from the beads due to the reducing 
environment dendritic cells generate in their phagosomes. This phenomenon has 
been shown to be mediated by the Gamma-interferon-inducible lysosomal thiol 
reductase (GILT) (126). Once released, the short peptides (particularly the N-
138 
 
terminal extended ones) would only need a little trimming (mediated by 
phagosomal petidases such as IRAP) before they were loaded onto phagosomal 
Class I. 
We thus fed siRNA treated dendritic cells with either N-extended 
CQLE(SIINFEKL) or C-extended (SIINFEKL)TEWC peptide beads. Our results 
have shown that efficient XPT of both these beads still depended on Rab39a 
(Figure 39). Because both N and C terminal extended beads were affected, we 
ruled out the possibility that Rab39a was specifically used to just recruit N or C 
terminal exopeptidases to the phagosome (such as IRAP) and hypothesized that 
Rab39a was instead affecting Class I loading. 
To further refine this experiment, we modified the SIINFEKL peptide 
through the generation of cysteine mutants (data not shown). We searched for a 
position in SIINFEKL wherein T cell recognition of the peptide MHC was not 
abolished even if this position was mutated to a cysteine. We found that 
CIINFEKL, bound to H2-Kb, was still able to be recognized by our reporter T cells 
(RF33-Luc). 
We now had a peptide that did not even require trimming. This peptide 
only needed to be released from beads – after which, it was ready to bind 
available Class I. When we fed siRNA treated cells with CIINFEKL beads, we 
observed that even with this form of antigen, efficient XPT required Rab39a 
(Figure 40). Rab39a rescue of knockout cells also increased XPT of this form of 
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antigen (Figure 41). Furthermore, this form of antigen was TAP-independent. 
This meant that CIINFEKL loading onto MHC Class I was occurring within the 
bead containing phagosome itself. This was because TAP1 is primarily used to 
transfer cytosolically processed peptides into the ER (127) or back into the 
phagosome (41). The CIINFEKL construct therefore was presented via a 
completely phagosomal route still dependent on Rab39a.  
 The same effect was seen when DCs were fed with a CSNENMETM flu 
peptide conjugated in the same manner (Figure 42). The peptide bound H2-Db 
and was recognized by reporter 12.64-Luc cells in a TAP independent but 
Rab39a dependent manner. Thus, Rab39a was shown to also affect loading on a 
different MHC-I allele. 
 The above results strongly supported our hypothesis that Rab39a was 
enhancing phagosomal Class I loading in the phagosomes, rather than affecting 
XPT through a different process such as pH modulation or antigen processing. 
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Figure 39. Rab39a sirna decreases presentation of disulfide conjugated peptide beads. 
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Figure 39. Rab39a sirna decreases presentation of disulfide conjugated 
peptide beads. 
2.5 x10
3
 DC3.2R cells were transfected with 50 nM sirna using Lipofectamine 
RNAiMax in reducing agent free media (cDMEM). After 48 hours, 1 x 10
4
 Rf33-
Luc were added along with the indicated amounts of biomag conjugates. After 
overnight incubation (~18 hours), Luciferase activity of the T cells were read 
using Oneglo reagent (Promega).  Error bars indicate the standard deviation 
between triplicate wells. Data shown represents one experiment of > 3. All wells 
with antigen have p-values (ANOVA) < 0.05 between β2m or Rab39a vs 
negative control I-Ab. 
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Figure 40. Rab39a sirna decreases presentation of preformed peptide. 
Figure 40. Rab39a sirna decreases presentation of preformed peptide. 
2.5 x10
3
 DC3.2R cells were transfected with 50 nM sirna pools using 
Lipofectamine RNAiMax in reducing agent free media (cDMEM). After 48 hours, 
1 x 10
4
 Rf33-Luc were added along with the indicated amounts of biomag 
conjugates. After overnight incubation (~18 hours), Luciferase activity of the T 
cells were read using Oneglo reagent (Promega). Error bars indicate the 
standard deviation between triplicate wells. Data shown represents one 
experiment of > 3. All wells with antigen have p-values (ANOVA) < 0.05 between 
β2m or Rab39a vs negative control I-Ab. For CIINFEKL, none of the wells for 
Tap1 are significant vs the control. 
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Figure 41. Rab39a rescue of knockout DCs increases crosspresentation of peptide beads. 
Figure 41. Rab39a rescue of knockout DCs increases crosspresentation 
of peptide beads. 
1.25x10
4
 DC3.2-Rab39aKO-Rab39a cells were incubated with 1 µg/ml dox for 
48 hours in a 96 well plate. Then, the indicated amounts of biomag-CIINFEKL 
beads were added along with 5 x 10
4
 Rf33-Luc. After overnight incubation, 
luciferase activity from the T cells were quantified using Oneglo reagent 
(Promega). Error bars indicate the standard deviation between triplicate wells. 
Data shown represents one experiment of > 3. All wells with antigen have p-
values (ANOVA) < 0.05 between no dox and dox. 
0 2 0 4 0 6 0 8 0 1 0 0
0
2 0 0 0
4 0 0 0
6 0 0 0
8 0 0 0
x p t o f  d is u lf id e  lin k e d  C IIN F E K L
g  b e a d
R
L
U
n o  d ox
dox
143 
 
Figure 42. Rab39a sirna decreases presentation of bead bound preformed peptide.  
Figure 42. Rab39a sirna decreases presentation of preformed peptide. 
2.5 x10
3
 DC3.2R cells were transfected with 50 nM sirna pools using 
Lipofectamine RNAiMax in reducing agent free media (cDMEM). After 48 hours, 
1 x 10
4
 Rf33-Luc were added along with the indicated amounts of biomag 
conjugates. After overnight incubation (~18 hours), Luciferase activity of the T 
cells were read using Oneglo reagent (Promega).   
This experiment was performed by Jeff Colbert 
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M. Rab39a increases open conformers in phagosomes 
Our findings that showed that Rab39a is required for the optimal XPT of 
an antigen that neither requires processing nor cytosolic transfer led us to 
hypothesize that Rab39a facilitates either delivery of MHC Class I to the 
phagosome, and/or peptide loading on MHC Class I already present there. To 
study this, we transduced the conditional Rab39a knockout DC line with H2-Ld, a 
Class I allele not normally present in C57BL/6 mice from which the DC line was 
derived. H2-Ld was a useful tool for studying peptide-Class I loading because 
there were antibodies that specifically recognized peptide empty forms (64-3-7 
antibody) or peptide occupied forms (30-5-7s antibody) of the Class I molecule 
(128). This would help us measure phagosomal Class I loading. 
Analysis of phagosomes derived from Rab39a positive cells showed a 
unique pattern of open and closed H2-Ld (Figure 43). While the majority of 
phagosomes were either negative or very low in either form of H2-Ld, a subset of 
these vesicles contained moderate to high amounts of both. There was also a 
subpopulation that mainly contained just the open or just the closed form of H2-
Ld. An interesting finding of this assay was that in Rab39a KO cells (-dox), there 
was a significantly lower subset of phagosomes with only open H2-Ld molecules 
as compared to the Rab39a-reconstituted cells (+dox)  (Figure 44). Rescuing the 
KO cells with either the DN or CA forms of Rab39a did not recover this subset 
(Figure 45). This phenotype seemed to be specific for open H2-Ld molecules as 
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the levels of MHC Class II and Lamp1 in the phagosomes were not affected 
(Figure 46).
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Figure 43. Open and closed forms of H2-L
d
 are enriched in different subsets of phagosomes.
Beads alone Phg from H2-L
d
 
negative cells 
Phg from H2-L
d+
 
Rab39a
+
 cells 
Figure 43. Open and closed forms of H2-L
d
 are enriched in different subsets of phagosomes. 
1.25 x 10
5
 DC3.2-Rab39aKO-Rab39a-L
d
 cells were incubated with 1 µg/ml dox for 48 hours in a 12 well plate. 
Cells were fed at 1 bead / cell of biotinylated 6 µm magnetic beads for 2 hours. Phagosomes were isolated using 
the listed protocol. Isolated phagosomes were washed, permeabilized and stained for open and closed H2-L
d
 . As 
a control, phagosomes were also isolated from dendritic cells lacking H2-L
d
. Data shown represents one 
experiment of >3. 
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Figure 44. Open H2-L
d
 conformers is enriched in phagosomes from Rab39a positive cells. 
-dox 
(KO) 
+dox 
(rescue) 
Figure 44. Open H2-L
d
 conformers is enriched in phagosomes from 
Rab39a positive cells. 
1.25 x 10
5
 DC3.2-Rab39aKO-Rab39a-L
d
 cells were incubated with or without 1 
µg/ml dox for 48 hours in a 12 well plate. Cells were fed at 1 bead / cell of 
biotinylated  6 µm magnetic beads for 4 hours. Magnetic bead phagosomes 
were isolated using the listed protocol. Phagosomes were washed, 
permeabilized and stained for open (64-3-7) and closed (30-5-7s) forms of H2-
L
d
. Data shown represents one experiment of >3. 
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Figure 45. Only the wt form of Rab39a is able to increase open H2-L
d
 in the phagosomes. 
-dox (KO) +dox (rescue) 
wt 
DN 
CA 
Figure 45. Only the wt form of Rab39a is able to increase open H2-L
d
 in the 
phagosomes. 
1.25 x 10
5
 of cells with wt, DN or CA Rab39a were incubated with or without 1 
µg/ml dox for 48 hours in a 12 well plate. Cells were fed at 1 bead / cell of 
biotinylated  6 µm magnetic beads for 4 hours. Magnetic bead phagosomes 
were isolated using the listed protocol. Phagosomes were washed, 
permeabilized and stained for open and closed forms of H2-L
d
. Top panels 
representing wt Rab39a are the same as in the previous figure (Figure 44). Data 
shown represents one experiment of >3. 
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Figure 46. Rab39a rescue does not change phagosomal MHC Class II or Lamp-1 levels. 
-dox (KO) +dox (rescue) A. 
B. 
No dox (KO) 
Dox (rescue) 
beads alone 
Figure 46. Rab39a rescue does not change phagosomal MHC Class II or 
Lamp-1 levels. 
(A) 1.25 x 10
5
 DC3.2-Rab39aKO-Rab39a-L
d
 cells were incubated with or 
without 1 µg/ml dox for 48 hours in a 12 well plate. Cells were fed at 1 bead / 
cell of biotinylated  6 µm magnetic beads for 4 hours. Magnetic bead 
phagosomes were isolated using the listed protocol. Phagosomes were 
washed, permeabilized and stained for MHC Class II (I-A / I-E) and Lamp1. (B) 
Shown are phagosomal gMFI of indicated stains. Data shown represents one 
experiment of >3. 
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i. Rab39a does not increase surface open or closed forms 
of H2-Ld 
The increase in open conformers mediated by Rab39a was found 
selectively in phagosomes, as steady state cell surface levels of both open and 
closed H2-Ld were not affected (Figure 47). Incubating the cells at 25oC 
increased overall Class I on the surface by allowing trafficking of unstable Class I 
from the ER and slowing down their internalization from the surface. Knockout 
and rescued cells had similar levels of H2-Ld despite this. Because of this finding, 
we hypothesized that the overall increase of open MHC Class I in the 
phagosomes mediated by Rab39a was not due to an overall increase in Class I 
expression. 
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Figure 47. Rab39a rescue does not change cell surface levels of open or closed H2-Ld. 
37
o
C 
25
o
C 
Open H2-L
d
 Closed H2-L
d
 
A. 
B. 
No dox (KO) 
Dox (rescue) 
Unstained cells 
Figure 47. Rab39a rescue does not change cell surface levels of open or 
closed H2-Ld.
 
 
1.25 x 10
5
 DC3.2-Rab39aKO-Rab39a-L
d
 cells were incubated with or without 1 
µg/ml dox for 24 hours at 37
o
C in a 12 well plate. Then, cells were transferred 
to either (A) 37
o
C or (B) 25
o
C for overnight incubation. Cells were detached and 
stained for the open and closed forms of H2-L
d
. Data shown represents one 
experiment of >3. 
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N. Phagosomal open conformers of Class I can be loaded with 
peptide 
Open forms of Class I in the phagosome could potentially be ones that 
become loaded with peptides. Thus, with the antigen, phagosomal proteases / 
trimming peptidases (27), components of the peptide-loading complex (40, 41) 
and now the MHC Class I molecule itself, the phagosome becomes a self-
contained organelle capable of crosspresentation.  
The 64-3-7 antibody used in our assays detected open forms of MHC 
Class I whether the Class I was bound to β2-microglobulin (β2m) or was β2m 
free (129). It has been shown that β2m free Class I can be detected on the 
surface and can be utilized in other cell processes besides XPT, such as in NK 
cell recognition (130). Furthermore, open MHC Class I has been shown to be 
unstable and is internalized quickly for degradation (131, 132). Thus, it was 
important to determine whether the open H2-Ld enrichment found in the 
phagosomes of Rab39a positive cells can actually be used for antigen 
presentation. 
To do this, phagosomes were obtained from KO or Rab39a positive cells, 
permeabilized in vitro with saponin and pulsed with SPSYVYHQF, a peptide that 
can bind to H2-Ld (133). Figure 48 shows that with peptide, the open H2-Ld in the 
phagosomes decreased, while closed H2-Ld increased (though sometimes the 
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increase in closed H2-Ld was very small). This result showed that the form of 
Class I enriched in Rab39a positive cells was functional and peptide receptive. 
Pulsing with an irrelevant peptide (SIINFEKL) had no effect (Figure 49). It is 
important to note that the peptide pulsing experiments were performed in a β2m-
free solution (1%BSA-pbs). This showed that at least a fraction of the open 
conformers in the phagosomes must be associated with β2m and are ready to 
accept peptides. 
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Figure 48. A fraction of phagosomal open H2-Ld are peptide receptive. 
Open H2-L
d
 
Closed H2-L
d
 
No peptide 
10 µM S9F 
Beads alone 
Figure 48. A fraction of phagosomal open H2-Ld are peptide receptive. 
1.25 x 10
5
 DC3.2-Rab39aKO-Rab39a-L
d
 cells were incubated with 1 µg/ml dox 
for 48 hours in a 12 well plate. Cells were fed at 1 bead / cell of biotinylated  6 
µm magnetic beads for 1 hour. Isolated phagosomes were washed, 
permeabilized and pulsed for 3 hours with the indicated peptide at 25
o
C. 
Phagosomes were then washed and stained for the open and closed forms of 
H2-L
d
. Data shown represents one experiment of >3. 
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Figure 49. Only the correct peptide can load phagosomal open H2-Ld. 
Open H2-L
d
 
Closed H2-L
d
 
No peptide 
10 µM S8L 
10 µM S9F 
Beads alone 
Figure 49. Only the correct peptide can load phagosomal open H2-Ld. 
1.25 x 10
5
 DC3.2-Rab39aKO-Rab39a-L
d
 cells were incubated with 1 µg/ml dox 
for 48 hours in a 12 well plate. Cells were fed at 1 bead / cell of biotinylated  6 
µm magnetic beads for 4 hours. Isolated phagosomes were washed, 
permeabilized and pulsed for 3 hours with the indicated peptides dissolved in 
1% BSA-PBS at 25
o
C. Phagosomes were then washed and stained for the open 
and closed forms of H2-L
d
. Data shown represents one experiment of >3. 
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O. Phagosomal open conformers are sensitive to endosomal 
proteases 
The percentage of phagosomes that are solely enriched with open H2-Ld 
greatly varied between experiments, but in all cases, rescue with Rab39a 
increased this percentage at least twofold compared to KO cells. Because of this 
variability, we extensively searched for factors that might influence the 
appearance of this seemingly unique population of phagosomes. 
In this search, we have found that the open form of H2-Ld was extremely 
sensitive to protease degradation, as addition of a serine and cysteine protease 
inhibitor (Leupeptin) greatly enriched its levels in the phagosomes (Figure 50 and 
51). Interestingly, the closed form of H2-Ld was not increased, indicating that this 
form was resistant to degradation. Treatment of cells with bafilomycin, which not 
only inactivates proteases due to increasing pH but may also prevent receptor 
recycling (134), enriched both the open and closed forms of H2-Ld in the 
phagosomes.  
We have previously shown that Rab39a expression reduced degradation 
in the phagosomes (Figure 37). Thus, it was possible that Rab39a was enriching 
internalized open H2-Ld in the phagosomes by preventing their degradation. 
Interestingly, both open and Closed H2-Ld were mainly in phagosomes with little 
ova degradation (Figure 52). However, it was also possible that Rab39a was 
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directly involved in delivering Class I molecules to the phagosome rather than 
just facilitating Class I persistence.
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Figure 50. Open and closed forms of H2-L
d
 are differentially affected by inhibitors. 
 
media 100 µM Leupeptin 25 nM bafilomycin 
Figure 50. Open and closed forms of H2-L
d
 are differentially affected by inhibitors. 
1.25 x 10
5
 DC3.2-Rab39aKO-Rab39a-L
d
 cells were incubated with 1 µg/ml dox for 48 hours in a 12 well plate. 
Cells were fed at 1 bead / cell of biotinylated ova conjugated to 6 µm magnetic beads for 4 hours with the indicated 
inhibitors. Phagosomes were isolated using the listed protocol. Isolated phagosomes were washed, permeabilized 
and stained for open and closed H2-L
d
. Data shown represents one experiment of >3. 
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Figure 51. Open and closed forms of H2-L
d
 are differentially affected by inhibitors.
100 µM Leupeptin   
25 nM bafilomycin 
media 
Beads alone 
Figure 51. Open and closed forms of H2-L
d
 are differentially affected by inhibitors. 
1.25 x 10
5
 DC3.2-Rab39aKO-Rab39a-L
d
 cells were incubated with 1 µg/ml dox for 48 hours in a 12 well plate. 
Cells were fed at 1 bead / cell of biotinylated ova conjugated to 6 µm magnetic beads for 4 hours with the indicated 
inhibitors. Phagosomes were isolated using the listed protocol. Isolated phagosomes were washed, permeabilized 
and stained for open and closed H2-L
d
 as well as ovalbumin. Shown are phagosomal gMFI of indicated stains. 
Data shown represents one experiment of >3. 
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Figure 52. H2-L
d
 is enriched in less degradative phagosomes. 
-dox (KO) +dox (rescue) 
Figure 52. H2-L
d
 is enriched in less degradative phagosomes. 
1.25 x 10
5
 DC3.2-Rab39aKO-Rab39a-L
d
 cells were incubated with or without 1 
µg/ml dox for 48 hours in a 12 well plate. Cells were fed at 1 bead / cell of 
biotinylated-ova conjugated to 6 µm magnetic beads for 4 hours. Isolated 
phagosomes were washed, permeabilized and stained for ovalbumin and 
open/closed H2-L
d
. Arbitrary gates divide the plots to show distinct phagosome 
populations. Data shown represents one experiment of >3. 
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P. Brefeldin A reduces Rab39a-dependent open H2-Ld molecules 
in phagosomes.  
In order to shed light on the source of the enriched open H2-Ld we 
observed in the phagosomes, we treated Rab39a knockout or rescued cells with 
brefeldin A (BFA). The rationale of this was that if the MHC molecules were 
coming from the ER-golgi compartment, then BFA would block it. Surface derived 
MHC would in contrast be resistant to short term brefeldin A treatment. 
PhagoFACS analysis has shown that when DCs were treated with BFA, 
Rab39a expression failed to increase the subset of phagosomes enriched with 
open H2-Ld (Figure 53). This suggested that MHC Class I was coming from an 
internal source (presumably the ER-golgi compartment) and were being 
delivered to the phagosome in part by Rab39a. As BFA was added along with 
the beads, surface Class I levels remained intact just prior to phagocytosis. If the 
increase in phagosomal Class I was due to surface MHC, then BFA should have 
had no effect. 
 On the other hand, we also observed that BFA abolished the inhibition of 
phagosomal antigen degradation conferred by Rab39a (Figure 54). Thus, it was 
possible that Rab39a was delivering stabilizing factors such as cathepsin 
inhibitors (cystatins) to the phagosome. Since MHC open conformers were 
sensitive to degradation (Figure 50), the Rab39a-mediated delivery of these 
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factors might be the reason why open MHC was enriched in the phagosomes, 
rather than direct delivery of MHC to these compartments. 
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Figure 53. Brefeldin A abolishes phagosomal H2-L
d
 enrichment conferred by Rab39a. 
-dox (KO) +dox (rescue) 
media 
+BFA 
Figure 53. Brefeldin A abolishes phagosomal H2-L
d
 enrichment conferred 
by Rab39a. 
1.25 x 10
5
 DC3.2-Rab39aKO-Rab39a-L
d
 cells were incubated with or without 1 
µg/ml dox for 48 hours in a 12 well plate. Cells were fed at 1 bead / cell of 
biotinylated-ova conjugated to 6 µm magnetic beads for 4 hours with or without 
1:1000 golgiplug. Isolated phagosomes were washed, permeabilized and 
stained for open/closed H2-L
d
. Data shown represents one experiment of >3. 
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Figure 54. Brefeldin A abolishes phagosomal inhibition of degradation conferred by Rab39a. 
media 
+BFA 
No dox 
Dox 
beads alone 
Figure 54. Brefeldin A abolishes phagosomal inhibition of degradation 
conferred by Rab39a. 
1.25 x 10
5
 DC3.2-Rab39aKO-Rab39a-L
d
 cells were incubated with or without 1 
µg/ml dox for 48 hours in a 12 well plate. Cells were fed at 1 bead / cell of 
biotinylated-ova conjugated to 6 µm magnetic beads for 4 hours with or without 
1:1000 golgiplug. Isolated phagosomes were washed, permeabilized and 
stained for ovalbumin. Data shown represents one experiment of >3. 
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Q. Brefeldin A blocks Rab39a recruitment to the phagosomes 
Our previous data showed that Rab39a was perhaps involved in bringing 
ER-derived components to the phagosome. These components might include the 
MHC Class I molecule. In order to determine if Rab39a shuttled from ER-golgi 
compartments to the phagosomes, we looked at the effect of BFA treatment on 
phagosomal Rab39a. 
Recruitment of Rab39a to the bead containing phagosome was inhibited 
by addition of BFA (Figure 55). In contrast to this, Rab7, implicated in controlling 
endosome maturation and lysosome biogenesis (135), reached the phagosomes 
despite BFA treatment. Phagosomal Lamp1, a component of the lysosome and 
another marker for phagosome maturation (136), was also not decreased (Figure 
56). These data showed that BFA treatment still allowed phagosome maturation 
to occur normally, and Rab39a was not likely playing a role in this process. 
Rab39a might instead have been delivering ER-golgi derived components to the 
developing phagosome, as disruption of this compartment reduced phagosomal 
Rab39a. Perhaps the non phagosomal GDP bound form of Rab39a was 
localized to non phagosomal organelles such as the ER-golgi compartment, and 
once activated shuttled cargo from these sources to the phagosome.  
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Figure 55. Brefeldin A inhibits Rab39a but not Rab7 recruitment to the phagosome. 
Figure 55. Brefeldin A inhibits rab39a but not rab7 recruitment to the 
phagosome. 
1.25 x 10
5
 DC3.2-Rab39aKO-Rab39a-L
d
 cells were incubated with or without 1 
µg/ml dox for 48 hours at 37
o
C in a 12 well plate. Cells were fed at 1 bead / cell 
of biotinylated-ova 6 µm magnetic beads for 3 hours with or without 1:1000 BFA 
(golgiplug, BD). Phagosomes were isolated using the listed protocol. Isolated 
phagosomes were washed, permeabilized and stained. Below are phagosomal 
gMFI of indicated stains. *Rab39a stained via HA-tag. Data shown represents 
one experiment of >3. 
No dox dox dox + BFA 
2ndary Ab 
No dox 
dox 
Dox + BFA 
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Figure 56. Brefeldin A inhibits Rab39a but not Lamp1 recruitment to the phagosome. 
Figure 56. Brefeldin A inhibits rab39a but not Lamp1 recruitment to the 
phagosome. 
1.25 x 10
5
 DC3.2-Rab39aKO-Rab39a-L
d
 cells were incubated with or without 1 
µg/ml dox for 48 hours at 37
o
C in a 12 well plate. Cells were fed at 1 bead / cell 
of biotinylated-ova 6 µm magnetic beads for 3 hours with or without 1:1000 BFA 
(golgiplug, BD). Phagosomes were isolated using the listed protocol. Isolated 
phagosomes were washed, permeabilized and stained. Below are phagosomal 
gMFI of indicated stains. *Rab39a stained via HA-tag. Data shown represents 
one experiment of >3. 
No dox dox dox + BFA 
2ndary Ab 
No dox 
dox 
Dox + BFA 
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R. Rab39a expression increases Sec22b levels in the phagosome 
Because Rab39a was seemingly shuttling components of the ER-golgi 
compartment to the phagosome, we looked at how Rab39a affected Sec22b, an 
ERGIC localized SNARE that was published to be important in XPT (59). In that 
study, Sec22b knockdown caused a defect in XPT and an increase in 
phagosomal degradation of antigen. Knockdown of the gene also did not cause a 
defect in MHC Class II presentation, similar to our results. Sec22b, along with 
syntaxin 4, was shown to mediate delivery of ERGIC derived components to the 
phagosome. These components included known players of the PLC (TAP, 
Tapasin, Calnexin). It was also proposed that the delivery of ERGIC components 
to the phagosome promotes phagosome to cytosol transfer of antigens. 
We used phagoFACS to determine if Sec22b levels in phagosomes from 
KO or Rab39a rescued cells were changed. When Rab39a knockout or rescued 
cells were fed with beads, we observed that Sec22b levels were increased 
(~25%) in phagosomes from rescued cells (Figure 57). We also observed a very 
small (~10%) but consistent increase in the levels of phagosomal TAP1 upon 
rescue with Rab39a (Figure 58). This was in agreement with the previous worked 
that showed PLC delivery to the phagosomes was mediated by Sec22b (59).  
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Figure 57. Rab39a recruits Sec22b to phagosomes. 
No dox (KO) 
Dox (rescue) 
beads alone 
Figure 57. Rab39a recruits Sec22b to phagosomes. 
1.25 x 10
5
 DC3.2-Rab39aKO-Rab39a-L
d
 cells were incubated with or without 1 
µg/ml dox for 48 hours at 37
o
C in a 12 well plate. Cells were fed at 1 bead / cell 
of biotinylated 6 µm magnetic beads for 3 hours. Phagosomes were isolated 
using the listed protocol. Isolated phagosomes were washed, permeabilized 
and stained for Sec22b. Shown are phagosomal gMFI of indicated stains. Data 
shown represents one experiment of >3. 
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Figure 58. Rab39a expression increases Sec22b and Tap1 levels in the phagosome. 
No dox 
Dox 
Cells alone 
Figure 58. Rab39a expression increases Sec22b and Tap1 levels in the 
phagosome. 
1.25 x 10
5
 DC3.2-Rab39aKO-Rab39a-L
d
 cells were incubated with or without 1 
µg/ml dox for 48 hours at 37
o
C in a 12 well plate. Cells were fed at 1 bead / cell 
of biotinylated 6 µm magnetic beads for 3 hours. Phagosomes were isolated 
using the listed protocol. Isolated phagosomes were washed, permeabilized 
and stained for Sec22b and Tap1. Below are phagosomal gMFI of indicated 
stains. Data shown represents one experiment of >3. 
No dox (KO) +dox (rescue) 
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IV. Discussion  
  Through a genomewide siRNA screen, we have identified Rab39a as a 
gene involved in XPT. Despite being a Rab GTPase associated with late 
endosomal compartments, loss of Rab39a inhibited only XPT, while leaving 
Class II presentation intact. The presentation of endogenously expressed 
proteins through the Classical Pathway was also unaffected. This led us to 
hypothesize that Rab39a affected XPT at the phagosome level. Experiments 
using TAP independent antigens, including preformed MHC peptides conjugated 
to beads further supported this hypothesis. 
Our experiments showed that expression of Rab39a inhibited degradation 
in the phagosomes. This could lead to the interpretation that Rab39a enhanced 
XPT by promoting antigen persistence. Supporting this, previous studies have 
shown that dendritic cells, as opposed to macrophages, had the capability to 
modulate phagosomal protease activity (73, 125). This inhibition of degradation 
can also be used to explain how a peptide bead (CIINFEKL) still required 
Rab39a activity for XPT despite having no need for processing. The effect of 
Rab39a on phagosomes may have led to the preservation of very sensitive 
antigens (such as short peptides) and provided the necessary time and peptide 
concentration for optimal loading to MHC Class I. 
While Rab39a may very well exert its effects through the modulation of 
antigen degradation, we have also shown that Rab39a expressing cells still had 
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XPT advantages over knockouts despite the deliberate inhibition of phagosomal 
proteases. Even in the presence of Leupeptin, Rab39a expression caused an 
increase in XPT. Moreover, the form of antigen we used (biomag-ova) depended 
little on phagosomal proteases, and mostly required cytosolic processing through 
the proteasome to generate the necessary MHC-I peptides.  
Though previous studies have demonstrated that magnetic bead 
conjugated ova was both proteasome and TAP dependent, we have shown that 
reducing ova to the minimal peptide (in our case CIINFEKL), removed this 
dependency. The antigen, despite being conjugated to the same bead material, 
became TAP independent, being loaded onto Class I in the phagosome itself 
similar to the vacuolar pathway that certain antigens route to. Loss of Rab39a still 
diminished presentation of this antigen. This led us to hypothesize that Rab39a 
was playing a role not in antigen processing, but in the phagosomal loading of 
peptides onto Class I. We wondered if the role of Rab39a was to deliver Class I 
to the phagosome. 
 
Through the use of phagosome flow cytometry, we have shown that 
expression of Rab39a increased the levels of open MHC Class I in the 
phagosomes. This increase was specific, as other phagosomal molecules such 
as MHC Class II and Lamp 1 were not affected. The significance of this finding 
was that a fraction of these open conformers were shown to be peptide 
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receptive. The presence of peptide receptive MHC-I in the phagosome explains 
how peptides can be loaded onto Class I while bypassing the ER. Both the 
vacuolar (CatS dependent) and IRAP dependent (P2C2P) pathways do not 
undergo an ER transport step, and Rab39a may provide the necessary Class I 
for their loading.  
One of the lingering questions in the field of XPT pertains to the source of 
phagosomal MHC Class I. Some antigens are released into the cytosol for 
proteasomal processing but then go back into the phagosome through TAP for 
N-terminal trimming and Class I loading (41, 43). Other antigens do not need to 
leave the phagosome at all, and require phagosomal proteases (27). These two 
observations indicate that functional MHC Class is in the phagosomes ready to 
receive peptides. How MHC Class I reaches the phagosomes and in what form is 
under intensive study. Several models have been proposed for this.  
One of the models proposed that surface MHC molecules can be 
internalized with the antigen, and, with low pH and the activity of proteases, 
these MHCs can be loaded with crosspresented antigen peptides (65, 66, 119). 
A unique property of fully formed peptide-MHC Class I to recycle back to the 
surface instead of being degraded in the lysosomes then allowed XPT. To further 
complicate matters, it has been shown that both the closed (peptide bound) and 
open (peptide free) forms of Class I were present on the surface and were 
internalized (131). This being the case, were peptides loaded on internalized 
closed or open MHC molecules? Lucin et al. has shown that the two forms did 
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not traffic equally - it was the open form of Class I that reached late endosomal 
compartments while the closed form was rapidly recycled back to the surface 
(137-139).  
We hypothesize that it is the open form of MHC Class I that accepts 
peptides destined for XPT. It is the form present throughout 
endosome/phagosome maturation, where the antigen undergoes continuous 
processing. It is also the form that can most readily bind free peptide, as the 
closed form would require low pH and/or specialized chaperones to facilitate 
peptide exchange.  
Supporting this hypothesis, our results showed that through Rab39a, the 
levels of open MHC Class I in late phagosomes (>2hrs) were increased. At this 
time point, there was also very low levels of Closed MHC Class I. Thus, at the 
location where antigen was processed, the open form of Class I was the one 
present to receive XPT peptides. This was particularly important for antigens that 
routed through the vacuolar pathway, as these needed processing in late 
endosomes. Furthermore, a fraction of the open MHC Class I was peptide 
receptive. Addition of peptide alone to isolated phagosomes in a β2m-free 
solution was enough to facilitate Class I loading. This suggested that Rab39a 
allowed phagosomes, particularly late phagosomes, to become self-sufficient 
XPT compartments by increasing their peptide receptive Class I. 
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  If Rab39a increased open MHC in the phagosomes, how did it do so? 
This enrichment could be due in part through Rab39a mediated inhibition of 
degradation, as we have also shown that the open form of MHC-I was very 
sensitive to protease digestion. Thus, one could hypothesize that Rab39a caused 
an increase in phagosomal open conformers by preventing its degradation, 
rather than delivering them there. These open conformers could have come from 
the cell surface, internalized together with the magnetic bead antigen. 
On the other hand, we hypothesized that Rab39a mediated delivery of 
newly synthesized MHC Class I from the ER to the antigen containing 
phagosome. This was because our results have shown that the increase in open 
conformers, as well as the inhibition of degradation mediated by Rab39a, was 
abolished by BFA. Rab39a itself was inhibited from being recruited to the 
phagosomes upon BFA treatment. This suggested that Rab39a was coming from 
the ER-golgi before reaching the phagosome. If this was the case, then it might 
have been delivering ER-golgi components (which can include Class I and the 
PLC) to the antigen containing phagosome. Moreover, phagosomes from 
Rab39a positive cells had increased levels of Sec22b, an ER-golgi t-SNARE that 
conferred a strikingly similar phenotype to that of Rab39a (59). 
Sec22b was shown to inhibit antigen degradation in the phagosomes. It 
was also shown to mediate delivery of ER-golgi derived components to the 
phagosome. Of particular note were components involved in Class I presentation 
(TAP1, Tapasin, Calnexin, though Class I itself was not looked at). The delivery 
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of ER-golgi components also promoted phagosome to cytosol transfer of whole 
antigens. Thus, at least for particles/beads containing full length ovalbumin, 
Rab39a might have also played a role in this cytosolic transfer, by mediating 
delivery of Sec22b labeled vesicles to the phagosomes.  
The Sec22b data showed that the Rab39a-mediated delivery of ER-golgi 
components to the phagosome likely has multiple effects in XPT. Inhibition of 
degradation in the phagosomes promoted antigen and open MHC persistence. 
For whole antigens, ER-golgi components facilitated phagosome to cytosol 
transfer. For peptide and vacuolar pathway antigens, the enrichment of open 
MHC in the phagosome allowed for peptide loading.  
The phenomenon of nascent, MHC Class I molecules being delivered to 
the antigen containing compartment has been described before, in the context of 
human DC presentation of long peptides (120). In that model, it was proposed 
that nascent MHC, loaded with suboptimal peptide, were delivered to the 
endosome through a novel secretory mechanism independent of Sec22b and 
CD74. The delivered MHC, with unstable peptide, then underwent peptide 
exchange with the more stable long peptide antigen. While our results showed 
that Rab39a expression increased both Sec22b and open conformers of H2-Ld in 
the phagosome, we could not definitively say that the increase in open 
conformers was due to Sec22b recruitment. It was possible that Rab39a may 
also have played a role in the proposed MHC-I secretory mechanism. It would 
also be very interesting to see if the open conformers we observed in the 
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phagosome arrived there already peptide free, or were in fact MHC with 
suboptimal peptides that have subsequently lost their cargo. 
Another model for phagosomal MHC trafficking, proposed by Nair-Gupta 
et.al (71), involved a pool of MHC Class I molecules in a compartment distinct 
from the ERGIC, which were then recruited to phagosomes containing TLR4 
ligand. The antibody they used for their experiments was AF6-88.4; this antibody 
recognized the closed form of H2-Kb as pulsing H2-Kb positive cells with 
SIINFEKL peptide increased staining (our unpublished data). Thus, their 
experiments showed an intracellular pool of peptide bound Class-I molecules 
being trafficked to the phagosome. How these closed molecules were loaded 
with new crosspresented peptides is unclear – as loaded Class I molecules are 
not known to readily exchange peptides. Perhaps the open form of H2-Kb also 
resided in this intracellular pool and was recruited similarly. It was also possible 
that TLR ligand containing phagosomes recruited other factors such as pH 
modulators and chaperones that mediated peptide exchange, similar to what 
happens in the MHC Class II pathway. Their experiments have shown that this 
trafficking of Class I was independent of Sec22b, which suggested that this 
pathway might be distinct from the phenomenon we have observed. 
Furthermore, we have performed our experiments using both ova coated beads 
(which might contain LPS) and plain biotinylated beads (which have no LPS) and 
saw similar results. This suggested multiple pathways of phagosome MHC 
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recruitment - that mediated by Rab39a/Sec22b and that of a Rab11a/Snap23 
related pathway involved in TLR containing antigen. 
Several studies could provide some insight on the possible role for 
Rab39a in bridging internal cellular components and the phagosomal 
compartment. In a study involving the intracellular parasite Chlamydia, it was 
shown that Rab39a was recruited to the bacterial inclusions (108). Its proposed 
role was to deliver multivesicular bodies, as well as spingolipids to the 
parasituous vacuole, which are then used for parasite growth. Interestingly, that 
study also showed that Rab39a labeled a subset vesicles that were Lamp1 
positive but lacked Cathepsin D. Perhaps this could explain the reduction of 
antigen degradation we have observed. Another group performed an extensive 
study to characterize the interactions of various Rab GTPases in dendritic cells 
(140). They have shown that Rab39a, which is late endosomal, was able to 
interact with the golgi localized Rab39b. Furthermore, at least in Neuro2A cells, 
both Rab39a and b shared a common effector, UACA (uveal autoantigen with 
coiled-coil domains and Ankyrin repeats) (104). Thus it is possible that Rab39a 
played a role in mediating ER-golgi and endosome/phagosome interactions. 
The contribution of the ER and other organelles to the formation of 
phagosomal membranes is not a new idea, but its contribution to XPT is the 
subject of intense debate. When attempting to eat particularly large antigen, 
phagocytes such as macrophages have been shown to recruit membranes from 
organelles in order to facilitate engulfment. This was termed “frustrated 
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phagocytosis” (141, 142). When macrophages were exposed to a surface coated 
with immune complexes, the cells tried to eat it. The impossibly large size of the 
surfaced caused macrophage golgi (141) and lysosomal (142) compartments to 
localize to the site of phagocytosis, to potentially contribute extra membrane. In 
dendritic cells, it was observed that latex bead phagosomes acquired proteins 
normally localized in the ER (61). These included transporters such as Sec61, 
Sec62, and TAP, as well as members of the PLC (Calnexin, Tapasin, Erp57). 
Therefore, it was proposed that dendritic cells use ER derived membranes to 
form phagosomes, and these were delivered via ER-phagosome fusion. 
Moreover, as the ER contained the classical players of MHC I presentation, ER-
phagosome fusion was a proposed method to facilitate XPT directly in the 
phagosome compartment. 
However, other groups contended that ER-phagosome fusion did not 
occur (143). In that study, very little if any Calnexin and PDI (both ER localized 
proteins) were detected in phagosomes using electron microscopy. APCs were 
also made to express ER localized GFP through a fusion with KDEL, an ER 
retention sequence. When these cells were made to internalize beads, the 
investigators could find no trace of GFP on the phagosomes. In a modification of 
this experiment, avidin-KDEL was expressed on cells, which were subsequently 
fed with biotin-beads. Still, even with the increased sensitivity of avidin-biotin 
interactions, no pull down of ER avidin was observed. 
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A potential resolution to this debate was presented by Desjardins et.al. 
(144). Through proteomics, it was shown that bead-containing phagosomes 
isolated from macrophages did indeed contain ER resident proteins. What was 
novel about this work was that it was also found that only a subset of ER proteins 
was trafficking to the phagosomes. For instance, mVenus fused to Stx18 was 
found in the phagosome proteasome while GFP-KDEL was not. This work 
showed that while phagosomes could recruit membranes from the ER, the 
mechanism of this recruitment was probably not wholesale ER fusion. Perhaps 
the ER/ER-golgi compartment generated secretory vesicles that were then 
trafficked to phagosomes, similar to the classic secretion pathways. These 
vesicles would have required specialized adaptors and Rab GTPases to facilitate 
their proper targeting and trafficking. They would also have required proper 
SNARES to mediate fusion with their intended targets. Rab39a and Sec22b 
might have provided these requirements. 
While our data suggests a novel pathway for the XPT of both TAP 
dependent and independent antigens, several unanswered questions remain. 
First, we cannot definitively pinpoint the source of open MHC we observed to be 
enriched in the phagosomes. Both surface MHC or internal sources can 
contribute to this. This is complicated by the observation that Rab39a expression 
inhibits degradation in the phagosomes. Brefeldin A treated cells do not enrich 
open MHC in the phagosomes despite the presence of Rab39a. While this might 
imply that MHC is coming from within the cell, BFA might also block internally 
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derived phagosome modulators that limit antigen degradation. These modulators, 
which may include cystatins and Nox2, can contribute to the preservation of 
surface derived open MHC-I.  
In our phagosome FACS assays, we saw that only a small subset of 
phagosomes was enriched for open H2-Ld (while containing low levels of closed 
H2-Ld). While our experiments showed that rescue with Rab39a increased this 
population vis-à-vis the knockout, the percentage of this population varied 
between experiments. Despite our efforts, we were not able to find a way to 
increase this population besides using protease inhibitors. Treatment of cells with 
TLR ligands or recycling inhibitors did not seem to have any effect (data not 
shown). What we did observe was that this subset was more visible in later 
timepoints (>2 to 4 hours, kinetics data not shown). Because of this, we 
consistently fed cells with beads for 2-4 hours, in order to hopefully maximize this 
population. However, we could not find a timepoint that had consistently high 
numbers of these phagosomes as the percentage of these open MHC enriched 
phagosomes still varied between experiments. One possible explanation was 
that open H2-Ld was continuously being loaded by peptides in the phagosome, 
and the MHC, now closed, was being rapidly shuttled to the cell surface. Indeed, 
when we did experiments to determine the kinetics of phagosomal open and 
closed MHC, we observed that while majority of phagosomes were double 
positive for both MHC forms at very early timepoints (~15 mins, data not shown), 
the closed form of Class I disappears or is greatly decreased by 30 mins. The 
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open form on the other hand, gradually decreases but somehow is stabilized at 2 
hours and onwards, presumably by delivery of new open Class I (or by inhibition 
of degradation in the phagosomes). However, these observations must be 
verified by better controlled experiments as we had technical issues in 
synchronizing the phagocytosis of the beads by dendritic cells.  
Another unanswered question is how Rab39a expression manages to 
reduce phagosomal degradation. Both Rab39a and Sec22b have been shown to 
have this effect, but the mechanism is as yet unclear. One of the ways dendritic 
cells manage to do this is by recruiting Nox2 to the phagosomal membrane. 
Nox2 promotes ROS production, which in turn causes an increase in 
phagosomal pH. This prevents the activation of a variety of proteases, thus 
preserving phagocytosed antigen for efficient XPT.  
While we have attempted to address the role of Nox2 in our observed 
phenotype, the antibodies we used did not give sufficient signal in our 
PhagoFACS assays. Perhaps further optimization, or use of alternative assays 
such as confocal microscopy will be able to definitively look at the mechanism of 
antigen persistence mediated by Rab39a.   
A caveat in our analysis of phagosomes was that we were limited into 
observing magnetic bead containing vesicles. However, it has been shown that 
phagosomes undergo several fusion and fission events, many of which 
contribute to XPT. For instance, MHC Class I, once loaded by an optimal peptide 
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in the phagosome, was then shuttled to the surface for presentation. Though this 
mechanism is still under study, it has been proposed that vesicles, through the 
action of Rab11a and other effectors, budded out of the phagosome and were 
“recycled” back to the surface (145). These steps in XPT were missed in our 
PhagoFACS analysis as they were no longer part of our magnetic bead 
preparations. Another missing event was the activity of Rab39a before it reached 
the antigen/bead containing vesicle. It would be interesting to characterize the 
content and determine the precise source of the cargo Rab39a delivered to the 
phagosome. In previous studies, the GDP bound form of Rab39a was shown to 
be dispersed in the cell, while the GTP bound form was endosomal (108). 
Perhaps the GDP bound form allows Rab39a to gather cargo from non 
endosomal sources (such as the ER-golgi) and once activated by GTP, deliver 
them to phagosomes.  
Furthermore, while we propose that the delivery of open MHC Class I was 
responsible for the increase in crosspresentation by Rab39a positive cells, our 
phagoFACS experiments looked at the open and closed forms of a transduced 
H2-Ld molecule. However, our XPT experiments (with reporter T cells) made use 
of the endogenous H2-Kb expressed by the cells. This discrepancy was brought 
about by the lack of / availability of tools needed for the experiments. The 
reporter T cells which we used were only specific for peptides on H2-Kb (or Db for 
12.64 hybridoma) but only H2-Ld has antibodies for its open and closed forms. 
While the epitope recognized by the 64-3-7 antibody (for the open form of H2-Ld) 
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can be transferred to a synthetic construct of H2-Kb, the dendritic cells that we 
use already had their own endogenous H2-Kb, and this will complicate the 
results. While we believe that the trafficking of open H2-Kb is the same or very 
similar to that of H2-Ld, one must be aware that in our experiments, the open 
MHC that we have observed within the phagosomes are not the ones being used 
to present ovalbumin peptides to our reporter T cells.  
V.  Proposed model of Rab39a in XPT 
Given these data, we hypothesize that Rab39a regulates a transport 
mechanism that delivers ER-golgi derived vesicles to the developing phagosome. 
Perhaps the GDP bound form of Rab39a, that we failed to detect on magnetic 
bead phagosomes, localizes extraphagosomally, on membranes of the ER-golgi 
compartment or its associated vesicles. Once activated, the GTP bound form of 
Rab39a, via adaptors and the cytoskeleton, then delivers its cargo of Sec22b 
labelled vesicles to the phagosome. As SNARES are primarily used for vesicle 
fusion, Sec22b on the Rab39 delivered vesicle then mediates fusion. Thus, ER-
golgi derived components, which may include degradation inhibitors (eg 
Cystatins), the PLC and possibly MHC Class I itself, are delivered into the 
phagosome lumen where they would be available for crosspresentation. These 
factors enhance crosspresentation by promoting antigen persistence, allowing 
phagosome to cytosol transfer of antigen, providing Tap1 as a peptide re-entry 
point to the phagosome and enriching receptive open MHC Class I molecules for 
peptide loading (Figure 59).  
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 Figure 59. Model of Rab39a mediated enhancement of crosspresentation. 
Figure 59. Model of Rab39a mediated enhancement of crosspresentation. 
Rab39a mediates delivery of ER derived cargo to antigen containing phagosomes (1). 
These cargo include Sec22b (2) (for targeting phagosomes), factors that allow P2C 
transfer of antigen (proposed to be Sec61), members of the PLC such as Tap1, and 
open MHC-I molecules. Antigen is then transferred to the cytosol (3) for proteasome 
processing (4). The generated peptides enter through Tap1 to reach the ER (5a) or the 
phagosome (5b). After trimming by ERAP (6a) or IRAP (6b), peptides are loaded onto 
empty/open MHC Class I molecules (7a, 7b). Loaded MHCs are then trafficked to the 
surface for presentation to CD8 T cells. 
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VI. Conclusion 
In this work, we have successfully developed and utilized a genomewide 
siRNA screen to identify novel genes involved in XPT. The screen was able to 
identify genes that selectively affected the XPT or Class II pathways. These 
genes are currently under intense study (Cruz FM, Colbert JD, Merino E, 
Kriegsman BA). 
The genomewide siRNA screen identified Rab39a as a gene involved in XPT. 
This Rab GTPase had no previously published role in antigen presentation. 
Furthermore, this study characterized the mechanism of how Rab39a affected 
XPT. 
Through the use of both siRNA and CRISPR knockout cells, we have shown 
that Rab39a was selective for XPT, and did not affect the Classical Class I and 
the Class II pathways. We showed that Rab39a enhanced XPT of antigens that 
required cytosol trafficking, but also those that remained in the phagosome. Our 
data indicated that Rab39a did not do this by altering phagosomal pH or  just 
modulating antigen degradation. Rather, Rab39a was being utilized by the cell to 
mediate the delivery of ER-golgi derived cargo to the phagosomes. This cargo 
could contain members of the peptide loading complex as well as peptide 
receptive forms of the MHC molecule. Rab39a expression increased Sec22b 
levels in the phagosome, suggesting that the fusion of this ER-golgi cargo with 
the antigen containing phagosome was mediated by this SNARE protein. 
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